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 GENETIC DETERMINANTS OF SMOKING CESSATION 
Mindi Annette Styn, PhD 
University of Pittsburgh, 2006
 
Current findings related to nicotine addiction and related physiologic-metabolic processes create 
a biological basis to consider the role of interindividual genetic differences governing smoking 
behavior.  
This study examined associations between smoking cessation and a set of potential risk 
factors measured in a group of adult cigarette smokers participating in a computed tomography 
(CT) lung cancer screening program. The investigation of non-genetic factors focused on the 
relationship between CT results and smoking cessation. The investigation of genetic factors 
attempted to determine genetic influences on the relationship between the dopamine pathway and 
smoking cessation by examining genetic variation in the dopamine receptor 2 (DRD2: TaqIA, 
TaqIB, C957T, –141C Ins/Del) and dopamine transporter (SLC6A3). 
Participants were part of the Pittsburgh Lung Screening Study (PLuSS), a research based 
low-dose CT screening program containing current and former cigarette smokers, ages 50 to 79. 
These analyses were restricted to baseline smokers who indicated their smoking status at follow-
up. Non-genetic factors were assessed for all eligible members of the cohort; genetic factors 
were assessed for a subset.  
A CT scan of the lungs that resulted in a referral was significantly associated with 
abstinence (for more than 30 days) at one year. The relative risk of being abstinent at one year 
after receiving a CT referral was 1.39 (95% Confidence Interval (CI): 1.14-1.70). After 
controlling for the matching variables and other genotypes, the DRD2 TaqIA polymorphism was 
significantly associated with being abstinent at one year (p=0.01). Compared to participants with 
the A2A2 genotype, participants who carried at least one variant allele (A1) were less likely to be 
abstinent (Odds Ratio: 0.47, 95% CI: 0.24-0.94). SLC6A3 genotype was not associated with 
abstinence at one-year (p=0.757). No significant gene-gene interaction with TaqIA was observed. 
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CT screening can create a “teachable moment” for smoking interventions. The 
association between TaqIA and abstinence at one year supports the hypothesis that genetic 
variation in the dopamine pathway influences smoking cessation.  
Public Health Significance: Smoking is the leading preventable cause of death in the 
United States. Identifying genetic variations that influence smoking behaviors could enhance 
treatment options for smoking cessation. This dissertation identified both non-genetic and 
genetic influences on smoking cessation. Consideration of those influences in the selection of 
quitting regimens may improve success rates thereby reducing the morbidity and mortality due to 
continued cigarette smoking. 
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PREFACE 
Nomenclature 
The primary analyses used in this dissertation project focused on individuals in PLuSS 
who were smoking cigarettes at baseline (baseline smokers). At the annual study update, 
approximately one year after enrollment into PLuSS, participants provided information on their 
cigarette smoking status. This information was used to define groups for the analyses. 
A “quitter” was defined as a baseline smoker, who one year later, reported having tried to 
quit smoking over the preceding year. 
A “successful quitter” was defined as a baseline smoker, who one year later, reported not 
smoking cigarettes for more than 30 days. In this dissertation the terms “abstinent at one year” 
and “quit at one year” are synonymous with the primary term “successful quitter.” 
An “unsuccessful quitter” was defined as a baseline smoker who reported current 
cigarette smoking one year later despite an attempt to quit smoking over the preceding year. In 
this dissertation the terms “attempted to quit, but not abstinent at one year” is synonymous with 
the term “unsuccessful quitter.” 
A “nonquitter” is defined as a cigarette smoker who, one year later, reported not having 
tried to quit smoking over the preceding year. 
 
 
 xii 
1.0  INTRODUCTION 
Current findings related to nicotine addiction and related physiologic-metabolic processes create 
a strong biological basis to consider the role of interindividual genetic differences governing 
cigarette smoking behavior. The capability to identify and to understand interindividual 
differences could be translated into more effective potentially pharmacologically based 
approaches to smoking prevention and treatment. This PhD dissertation paper presents primary 
results related to smoking cessation and genetic variability in two genes (DRD2 and SLC6A3) 
involved in dopamine pathways. To justify the investigation of the possible role of DRD2 and 
SLC6A3 in smoking cessation, the following text briefly summarizes current scientific 
knowledge regarding the genetic basis of cigarette smoking, with particular emphasis on 
dopamine-related genes. 
1.1 BACKGROUND AND SIGNIFICANCE 
The link between cigarette smoking and chronic disease is well established. The Center for 
Disease Control and Prevention (CDC) indicates that cigarette smoking is the leading 
preventable cause of death in the United States. Over 400,000 premature deaths occur annually 
because of cigarette smoking. Mortality rates for lung cancer, the leading cause of cancer death, 
are increased more than 10-fold for current smokers.[1] 
Cigarette addiction is a significant public health problem. Almost half of all adults have 
smoked in their lifetime and, of those adults who have smoked, over half continue to smoke. 
Although the prevalence of cigarette smoking has decreased over the past few decades in 
reaction to public health campaigns, many smokers are still unable to quit. According to the 
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National Health Interview Survey, 70% of smokers indicated that they wanted to quit; however, 
only 4.7% could abstain from smoking for at least three months.[2] 
Despite the various behavioral and pharmacological smoking cessation aides that are 
currently available, the vast majority (over 90%) of individuals who quit successfully do so 
without any assistance.[1] The limited effectiveness of cessation aides in the population may be 
due to interindividual differences in various aspects of smoking behavior including both the 
strength of addiction and the burden of withdrawal symptoms. These interindividual differences 
are partially dictated by genetics. Therefore, identification of and consideration of genetic 
influences on smoking behavior in the selection of quitting regimens may improve success rates. 
1.2 LITERATURE REVIEW 
1.2.1 Biological Plausibility of Genetic Influences on Smoking Behavior. 
Nicotine is considered the main addictive component of cigarettes. One way that nicotine 
induces addiction is by creating feelings of pleasure in smokers. The main reward pathway acted 
upon by nicotine is the dopamine pathway, which originates in the ventral tegmental area of the 
midbrain and extends into the forebrain, most significantly to the nucleus accumbens. [3, 4] 
Nicotinic acetylcholine receptors (nAChRs) on dopamine neurons trigger the release of 
dopamine into the synaptic cleft. The dopamine then activates dopamine receptors on the 
postsynaptic neurons to create the feelings of pleasure that are associated with smoking. 
Neurotransmission ends when dopamine is depleted from the synapse. Dopamine transporters on 
the presynaptic neuron ends are responsible for dopamine re-uptake. Dopamine in the synapse is 
also depleted when it is metabolized either to homovanillic acid by catechol-o-methyl transferase 
(COMT), monoamine oxidase A and B (MAO A, MAO B), and aldehyde dehydrogenase (ALD) 
or to norepinephrine by dopamine β-hydroxylase (DBH).[3-5]  
Smokers drive the dopamine reward pathway by making nicotine available in their 
bodies. However, variations along this pathway dictate the amount of nicotine a smoker needs. 
For example, the density and sensitivity of nAChRs vary among individuals and are altered with 
long-term exposure to nicotine. The receptors become desensitized leading to nicotine tolerance. 
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Ultimately these desensitized receptors become inactive and turnover more slowly. This slow 
turnover leads to increased receptor density. However, after an extended period of time without 
nicotine exposure, the inactive receptors become active again. Since these receptors are also 
involved in non-reward pathways, the activation of a large number of receptors may lead to the 
unpleasant symptoms of withdrawal and may explain why many addicted smokers report that 
their first cigarette of the day is their most enjoyable. [4] 
The efficiency of the pathway is also dictated by the amount of dopamine that is available 
to activate the dopamine receptors. Dopamine synthesis starts when the amino acid tyrosine 
enters the neuron and is converted to dihydroxyphenylalaine (L-DOPA) by tyrosine hydroxlyase 
(TH). [3, 5] Since this is considered the rate-limiting step in dopamine synthesis, variations in the 
TH gene may play a role in the effects of nicotine on the body and on smoking behaviors.  
The availability of dopamine is not solely influenced by the amount of dopamine created; 
it is also influenced by the rates of re-uptake and metabolism that remove dopamine from the 
synapse. Genetic variations in the dopamine transporter gene (SLC6A3), MAO A and B, and the 
COMT gene may influence the rates of reuptake and metabolism of dopamine.[5, 6] 
Activation of dopamine receptors causes the feelings of pleasure that smokers get from 
nicotine. The amount of activation is not only influenced by the amount of dopamine available, 
but also by the number, or density, of receptors. Five types of dopamine receptors, designated D1 
through D5, have been identified. Each of the dopamine receptor genes (DRD1 through DRD5) 
is polymorphic, and some of these polymorphisms such as the TaqIA polymorphism on DRD2 
have been shown to decrease receptor density.[7] Polymorphisms in the DRD2 gene have been 
implicated in studies of alcoholism and, thus, have been the most scrutinized in studies of other 
addictions including nicotine addiction. [3] 
To sustain the pleasurable effects of nicotine on the body, smokers must regulate nicotine 
levels in their bodies. This desire to maintain a steady state of nicotine dictates individual 
smoking behaviors such as how frequently a smoker smokes and how deeply the smoker inhales. 
When nicotine levels or the effects of nicotine on the body are artificially manipulated, smokers 
modify their smoking behaviors. For example, nicotine replacement therapy can successfully be 
used to reduce the number of cigarettes consumed by increasing the amount of nicotine available 
in the body. Alternatively, the drug mecamylamine, which blocks central nicotinic receptors and 
reduces the effects of nicotine, causes an increase in the number of cigarettes consumed.[8] 
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Nicotine levels in the body are drained by metabolism and elimination of nicotine. When 
cigarette smoke is inhaled, nicotine is absorbed through the lung epithelium and travels to the 
brain where it crosses the blood-brain barrier. Nicotine can be metabolized through three 
different pathways: C-oxidation, N-oxidation, and N-methylation. [6]  
The primary pathway for the metabolism of nicotine is C-oxidation in the liver by the 
cytochrome P450 enzyme CYP2A6, which produces cotinine.[5] CYP2A6 metabolizes 60 to 80 
percent of nicotine to cotinine.[6] Phenotyping studies done with the probe drug coumarin show 
interindividual variability in CYP2A6 activity in vivo.[9] A 30-fold variation in nicotine-to-
cotinine Vmax was found when CYP2A6 levels and activity were studied in human liver 
microsomes.[9, 10] Since CYP2A6 is the only enzyme that is able to produce the 7-hydroxy 
metabolite of coumarin, studies of the metabolite directly reflect CYP2A6 enzyme activity. [11]   
Based on our extensive knowledge of the physiology of nicotine addiction, we 
hypothesize that genetic variation, involving the genes mentioned above (COMT, MAO A, MAO 
B, ALD, DBH, TH, SLC6A3, CYP2A6, DRD1 through DRD5), might partially determine 
interindividual differences in smoking. This list is not exhaustive. Other investigators have 
hypothesized roles for additional genes including CYP2D6, CYP2A13, CYP2B6, orosomucoid 1 
(ORM1), alcohol dehydrogenase 3 (ADH3), opioid receptors OPRD1 and OPRM1, serotonin 
transporter (SLC6A4), serotonin receptors hydroxytryptamine 1D (HTR1D) and HTR1B, 
tryptophan hydroxylase (TPH), cholecystokinin (CCK) and acetylcholine receptor alpha-subunit 
(CHRNA7) ([12-17]). The genes DRD2 and SLC6A3 were selected as the focus of this work 
because of the interest in DRD2 in relation to alcoholism and addiction in general (see above) 
and the prominent role that SLC6A3 plays in nicotine reuptake. These two genes also potentially 
influence each other’s effect on smoking behaviors. 
1.2.2 Twin Studies  
The results of numerous twin studies conducted since the mid-twentieth century in various 
populations support a hypothesis that genotype is a major factor in smoking behavior.[3, 6] The 
reported heritability estimates have been as high as 84% (28 to 84%). Recent studies have 
investigated distinct phases of smoking behaviors, from initiation to dependence and persistence, 
and found support for genetic involvement across all phases. [3, 6, 18]. In a study of 2,163 
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female twins in Virginia, Kendler, et al., reported that the risk factors for initiation and 
dependence are related but not identical. Heritability rates for nicotine dependence were around 
72%.[19] In a study of 3,356 members of a male veteran twin pair registry the heritability of 
nicotine dependence was 60.3% (95% confidence interval: 55.4 – 65.2%).[20] Although twin 
studies have been valuable in establishing a genetic link to smoking behavior, they are unable to 
provide insight into which specific genes influence behavior. 
1.2.3 The DRD2 Gene 
As explained previously, the dopamine pathway is a major reward pathway implicated in 
addiction to nicotine and other drugs. Among the various dopamine receptors, DRD2 has 
received the most attention because of an early finding of an association between the TaqIA 
restriction fragment length polymorphism (RFLP) on the DRD2 gene, located on chromosome 
11q23, and alcoholism. This has led to DRD2 research for various addictions and disorders, 
including nicotine addiction. 
1.2.3.1 DRD2 Variants 
Many variants in the DRD2 gene have been found. We have selected TaqIA and TaqIB 
because of their importance in the literature with regard to smoking behaviors and C957T and –
141C Ins/Del because they are functional changes that have not been thoroughly investigated in 
relation to smoking cessation. 
Table 1 summarizes the frequencies of each variant in Caucasians, the nucleotide change 
associated with each variant, the reported effect of the change, and the location of each variant 
on chromosome 11. Table 2 summarizes a review of the literature for the allele frequencies in a 
variety of populations. 
1.2.3.2 Associations of Selected DRD2 Variants with Smoking Behaviors 
Of the selected DRD2 variants TaqIA is clearly the most common variant studied in 
relation to smoking behaviors (table 3). Although early studies were promising, findings from 
more recent studies have not strongly supported the hypothesis of a direct link between TaqIA 
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and smoking cessation but have reported interesting findings in relation to gender differences 
and cessation treatment.  
One of the earliest reports of a link between DRD2 variants and cigarette smoking was 
from a study conducted in 312 non-Hispanic Caucasian case subjects who were part of a 
smoking cessation clinic that targeted individuals who had at least one unsuccessful attempt at 
cessation. Control subjects were a combination of 235 subjects obtained by the investigators and 
479 subjects whose data were obtained by the investigators from abstracts presented in poster 
sessions. Control subjects were all screened to exclude problems with addiction other than 
tobacco. Two of the control subjects were smokers. The controls were in Hardy-Weinberg 
equilibrium, but the cases were significantly out of equilibrium. The frequency of the A1 allele 
was significantly different between cases (0.264) and controls (0.147). Relationships between 
other smoking related variables, such as age at initiation and maximum quit duration, and the A1 
allele were also reported.[21] 
A sample of 354 non-Hispanic Caucasian current smokers (n=57), former smokers 
(n=115) and nonsmokers (n=182) was genotyped for the A1 allele. The prevalence of the variant 
was significantly different among the three groups (p=0.018), and a significant trend was 
reported with the frequency of the allele increasing from nonsmokers to former smokers to 
current smokers. When all smokers (former and current) were compared to nonsmokers the odds 
ratio was 1.85. When this comparison was limited to current smokers only, the odds ratio 
increased to 2.15. [22] 
In a study of 104 smokers who smoked at least 5 cigarettes per day and 117 non-tobacco 
users who either never smoked or had not used any tobacco-containing product for at least 10 
years no association was found between the TaqIA variant and smoking status. This study was 
limited to Caucasians from the North East of England. [23] 
Researchers from the M.D. Anderson Cancer Center frequency matched a group of 126 
Caucasian control subjects to 157 newly diagnosed lung cancer patients. The case and control 
subjects were classified as never smokers and ever smokers who smoked more than 100 
cigarettes in their lifetime. Ever smokers who quit at least one year before the interview were 
further classified as former smokers. The association between having at least one TaqIA allele or 
at least one TaqIB allele was observed. The TaqIB variant was more common in ever smokers, 
but this was only statistically significant in controls. Relationships were also observed between 
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both the TaqIA and TaqIB variants and early smoking initiation and number of cigarettes smoked 
per day. It should be noted that ever smokers greatly outnumbered never smokers among both 
cases (142:15) and controls (113:13). [7] 
In a follow-up study conducted in 208 African-Americans and 154 Mexican-Americans 
with and without lung cancer the same group of researchers from M.D. Anderson Cancer Center 
identified relationships between DRD2 genotype and several smoking variables among control 
subjects only. Although few of these relationships reached statistical significance, they may be of 
interest for larger studies. Among the 111 Mexican-American controls the A1A1 genotype 
appeared to be positively related to smoking (20% were never smokers and 60% were current 
smokers) and the A2A2 genotype appeared to be negatively related to smoking (53.1% were 
never smokers and 28.1 % were current smokers). Similarly, among Mexican-American controls 
the B1B1 genotype appeared to be positively related to smoking (21.4% were never smokers and 
64.3% were current smokers) and the B2B2 genotype appeared to be negatively related to 
smoking (53.7% were never smokers and 19.5 % were current smokers). While a χ2 test for 
trend was strongly significant for the B1 frequency among never smokers, former smokers, and 
current smokers, the test for trend for the A1 frequency did not reach statistical significance. 
Relationships between genotype and age at initiation and quantity smoked were also 
reported.[24] 
These early reports have been questioned due to potential confounding that may have 
been introduced in the selection of the control populations.[5] 
Lerman, et al., reported that the SLC6A3-9 allele was found less frequently among a 
group of 289 smokers (smoked at least five cigarettes per day for at least 1 year) when compared 
to 233 non-smokers (smoked less than 100 cigarettes in their lifetime). No differences were 
found between smokers and non-smokers in the prevalence of the TaqIA variant; however, the 
study suggested that DRD2 might modify the effects of the dopamine transporter gene.[25]  
In a study of 332 Japanese individuals, the association between smoking and the TaqIA 
variant and the –141C Insertion/Deletion (Ins/Del) variant was examined. Subjects were 
classified as never smokers who smoked less than 100 cigarettes in their lifetime (n=198), former 
smokers who quit at least one year prior to the interview (n=57), and current smokers who may 
have quit within one year of the interview (n=77). The ever smokers group was a combination of 
the current and former smokers (n=134). In contrast to previous reports, the TaqIA wild type 
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genotype was significantly more frequent in the ever smokers than in the never smokers. No 
relationship between –141C Ins/Del and smoking status was observed.[26] 
A study of 101 male and 66 female Korean subjects with schizophrenia examined the 
relationship between the TaqIA allele and smoking behavior. Only smokers with a score greater 
than seven on the Fagerstrom test for nicotine dependence and non-smokers with no previous 
smoking experience were included in the study. The findings from this study are unique in that 
they present the hypothesis that the relationship between TaqIA and smoking shows gender-
specific molecular heterosis. Significantly more heterozygous males were smokers than 
homozygous males of either genotype (wild type or variant). Fewer heterozygous females were 
smokers than homozygous females of either genotype, but this did not reach statistical 
significance.[27] The findings of this report were further supported in a study in 187 healthy 
Korean subjects. The follow-up study used the same definitions for smokers and non-smokers. In 
males, this study reported significantly higher A1 allele frequency and prevalence in smokers 
compared to non-smokers. The data for females suggested an inverse relationship between 
smoking and allele frequency and prevalence, but these findings were not statistically significant. 
In females, significantly fewer heterozygotes were observed in the group of smokers.[28] 
Johnstone, et al., investigated the impact of DRD2 TaqIA on smoking behaviors among 
participants in the OXCHECK study, a large population based cohort study that was conducted 
in the United Kingdom. Current smokers were classified into four groups: low consumption (1-9 
cigarettes per day), mid consumption (10-19 cigarettes per day) and high consumption (20+ 
cigarettes per day). Three hundred participants were selected from each group and from the 
group of never smokers. A total of 975 participants were successfully genotyped. No 
associations were found between DRD2 TaqIA genotype and level of smoking consumption, 
smoking status (never smoker vs. current smoker) or age at smoking initiation.[29] 
Three studies have investigated the influence of DRD2 TaqIA genotype on the use of 
bupropion for smoking cessation. In a clinical trial of bupropion treatment for smoking cessation 
conducted in the United States, 418 participants of European Caucasian descent were randomly 
assigned to receive either a placebo (n=191) or bupropion (n=227) for 10 weeks along with 
standard behavioral counseling. All participants were successfully genotyped for both DRD2 
TaqIA and SLC6A3. Neither DRD2 TaqIA nor SLC6A3 genotype had a significant effect on 
smoking behavior at the end of treatment nor at the 6-month follow-up; however, SLC6A3 had a 
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significant effect on smoking cessation at the end of treatment for individuals with the TaqIA A2 
allele. In Logistic regression analyses the gene-gene interaction term was significant with the 
SLC6A3-9 allele being significantly associated with cessation at the end of treatment for 
individuals with the TaqIA A2 allele. This effect was not observed at 6-months post-treatment, 
and a significant time*DRD2*SLC6A3 interaction effect was observed.[30] Similarly among 451 
Caucasian participants in an open-label, randomized effectiveness study of bupropion and 
counseling for smoking cessation, Swan et al. found no significant difference in smoking 
cessation at one year and presence or absence of the A1 allele. However, among female 
participants, those with an A1 allele were significantly more likely to stop taking the bupropion 
than those without an A1 allele. The number of copies of the A1 allele that a woman carried was 
also associated with smoking cessation at one year. Women were significantly more likely to 
quit smoking if they carried more A2 alleles.[31] In a smaller randomized trial comparing 
bupropion to placebo (n=29) withdrawal cravings were measured among participants who had 
been on bupropion for two weeks. Those participants with carrying the A1 allele did not 
experience significant reductions in cravings while those with the A2A2 genotype did. This 
report did not address differences in smoking status with regard to genotype.[32] 
The strong biological rationale for the impact of DRD2 on smoking behaviors and the 
paucity of data available on the topic provide the impetus for us to look at this potential 
association. While the previous studies described above provide us with interesting research 
questions, the inconsistency of their results suggest that more research is needed on this variant. 
1.2.4 The SLC6A3 Gene 
The SLC6A3 gene is located on chromosome 5p15.3 and encodes the dopamine transporter 
(DAT) reuptake protein that removes dopamine from the synapse. The important role that DAT 
plays in removing dopamine from the synapse has led to research on SLC6A3 and various 
dopamine related disorders. Variations in a 40-base pair repeat, occurring primarily as a 9- or 10-
repeat, in the 3’ untranslated region are related variations in the density of transporter molecules 
on the surface of neurons.[33] 
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1.2.4.1 SLC6A3 VNTR Variant 
We selected the SLC6A3 VNTR variant because it is the most studied of the DAT genetic 
variants and because of previously reported association between this variant and DRD2.[25, 30] 
As previously stated, the SLC6A3 VNTR occurs primarily as a 9- or 10-repeat allele. The 
9-variant allele is considered the variant allele, and the 10-repeat is considered the wild type. 
Table 4 summarizes the frequencies of these alleles in Caucasians as well as the proposed effect 
of the allele. Table 5 summarizes a review of the literature for the allele frequencies in a variety 
of populations. 
1.2.4.2 Associations of SLC6A3 VNTR Variants with Smoking Behaviors 
We found five reports that investigated a link between SLC6A3 and smoking behaviors. 
Four of these addressed the specific issue of smoking cessation. The results of this literature 
review are shown in table 6. Initial reports of a main effect relationship between the SLC6A3-9 
allele and reduced smoking (either quitting or not smoking vs. smoking) were not replicated in 
subsequent studies. However, it is difficult to conclude whether or not this variant is significantly 
associated with smoking cessation because of the limited number of reports available.  
In a study of 1,107 individuals recruited through several National Institutes of Health 
protocols not specific to smoking cessation (cancer risk-related behaviors, personality genetics, 
sexual behavior), Sabol, et al., found a significant association between SLC6A3 genotype and 
smoking cessation among 593 nonsmokers (less than 100 cigarettes), 283 current smokers, and 
231 former smokers. The SLC6A3-9 allele was more common among former smokers compared 
to those who were current smokers.[34] 
In a previously described study, Lerman, et al., reported that the SLC6A3-9 allele was 
found less frequently among a group of 289 smokers when compared to 233 non-smokers. 
Although no differences were found between smokers and non-smokers in the prevalence of the 
TaqIA variant; however, the study suggested that DRD2 might modify the effects of SLC6A3. 
Caucasian participants with SLC6A3-9 genotypes were significantly more likely to be non-
smokers only among those participants with the TaqIA A2A2 genotype. A similar, but 
nonsignificant trend was seen among African-American participants.[25] In a subsequent 
randomized trial of bupropion for smoking cessation described earlier in this dissertation 
SLC6A3 was not significant as a main effect in the entire sample, but was significant among 
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participants with the DRD2 TaqIA A2A2 genotype. In the multivariate model in the entire sample 
the DRD2*SLC6A3 interaction term was significant.[30]  
In contrast, Vandenberg, et al., reported no relationship between SLC6A3 and smoking 
behavior among 595 randomly selected adult volunteers when the same group classifications 
were used that were used in the previously described reports by Lerman and Sabol (193 
nonsmokers who smoked <100 cigarettes, 88 former smokers, 48 current smokers). However 
contrary to the previously reported associations, when the 135 never-smokers (0 lifetime 
cigarettes) and 59 non-smokers (<100 lifetime cigarettes) were analyzed as separate groups, 
SLC6A3-10 was more frequent among never smokers. [33]  
Jorm, et al. found no association between the SLC6A3 gene and either smoking initiation 
or cessation in a community sample of 861 Caucasian participants from Australia. [35] 
1.3 OBJECTIVE 
The primary research findings from this PhD study of the genetic basis of cigarette smoking 
cessation are presented in the form of three distinct manuscripts. Each manuscript describes 
research results from the same research population, current 50 to 79 year old cigarette smokers 
followed for one year after entry into a research-based lung cancer screening program (the 
Pittsburgh Lung Screening Study, PLuSS). The first manuscript describes the association 
between questionnaire-based risk factors and cigarette smoking cessation one year after entry 
into PLuSS. The second and third manuscripts describe risk associations between cigarette 
smoking cessation and DRD2 (manuscript 2) and SLC6A3 (manuscript 3). 
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Table 1: A summary of the selected DRD2 polymorphisms. Frequencies are reported for Caucasians 
Allele Frequency Nucleotide Change Effect Chromosome Location ID Number
TaqIA 19.3%[21] 3' C>T Decreased receptor density [21, 28] 112776038[15] Rs1800497
TaqIB 17.0%[29] 3' A>G Unknown, but variant is closer to coding region than TaqIA [29] 
112801496[15] Rs1079597
C957T 57.0%[6] C957T Decreased stability of mRNA/Decreased protein synthesis [6]  
112788669[24] Rs6277 
-141C 
Ins/Del 11.0%[2] 
Deletion of  
-141 C Decreased promoter activity [1, 2, 31] 
112851462[15] Rs1799732
 
Table 2: Selected DRD2 polymorphisms, frequencies of the variant allele reported in the literature 
Author Geographic Area N 
Frequency 
Of Variant 
Allele 
TaqIA    
Lerman 
(1999)[21] 
USA 1044 Total: 
444 Caucasians 
78 African Americans 
 
0.193 
0.301 
Erblich 
(2004)[7] 
New York, East Harlem, 
USA 
108 smokers, predominately 
African American 
0.361 
Cinciripini 
(2004)[4] 
Texas, USA 134 Total 0.264 
Spitz (1998)[29] Texas, USA 283 Total: 
157 lung cancer cases 
126 controls 
0.222 
0.218 
0.228 
Wu (2000)[36] Texas, USA 
(limited to African-
Americans and Mexican-
Americans) 
357 Total: 
139 lung cancer cases 
218 controls 
0.387 
0.374 
0.394 
Comings 
(1996)[5] 
California, USA 
(limited to non-Hispanic 
Caucasians) 
424 Total: 
312 smokers at least 1 
unsuccessful quit attempt 
235 controls (includes smokers) 
0.270 
0.264 
 
0.277 
Lerman 
(2004)[22] 
USA  
(limited to smokers of 
European ancestry) 
71 Total 0.260 
Noble (1994)
[25] 
 Nevada and California, 
USA 
(Limited to non-Hispanic 
Caucasians) 
354 Total 0.196 
Johnstone 
(2004)[12] 
United Kingdom 975 Total: 
470 smokers 
145 never smokers 
0.200 
0.208 
0.197 
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Table 2 continued 
Author Geographic Area N 
Frequency 
Of Variant 
Allele 
TaqIA    
Gorwood 
(2000)[9] 
France 
(limited to males) 
162 Total: 
113 alcohol dependent 
49 controls 
0.395 
0.389 
0.408 
Xu (2004)[37] Germany 418 Total: 
227 heroin-dependent cases 
191 controls 
0.198 
0.194 
0.202 
Xu (2004)[37] China 799 Total: 
486 heroin-dependent cases 
313 controls 
0.392 
0.401 
0.379 
Lee (2003)[18] Korea 187 Total: 
94 Smokers 
93 Non-smokers 
0.41 
0.42 
0.40 
Lee (2002)[19] Korea 
(limited to schizophrenics)
167 Total: 
96 smokers 
71 never smokers 
0.47 
0.48 
0.47 
Suzuki 
(2000)[32] 
Japan 
(limited to schizophrenics)
25 Total 0.34 
TaqIB    
Spitz (1998)[29] Texas, USA 283 Total: 
157 lung cancer cases 
126 controls 
0.160 
0.166 
0.152 
Wu (2000)[36] Texas, USA 
(limited to African-
Americans and Mexican-
Americans) 
308 Total: 
117 lung cancer cases 
191 controls 
0.260 
0.231 
0.277 
Xu (2004)[37] China 772 Total: 
466 heroin-dependent cases 
306 controls 
0.538 
0.480 
0.587 
Xu (2004)[37] Germany 372 Total: 
266 heroin-dependent cases 
112 controls 
0.717 
0.720 
0.710 
Yoshida 
(2001)[38] 
Japan 332 0.357 
C957T    
Duan (2003) [6] USA 146 Total: 
94 European-American 
51 African-American 
0.40 
0.57 
0.09 
Lawford (2005)
[17] 
 Australia 
(limited to Caucasians) 
301 Total: 
153 schizophrenics 
148 controls 
0.521 
0.445 
0.581 
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Table 2 continued 
Author Geographic Area N 
Frequency 
Of Variant 
Allele 
-141C Ins/Del   
Xu (2004)[37] Germany 662 Total:  
471 heroin-dependent cases 
191 controls 
0.105 
0.104  
0.107  
Xu (2004)[37] China 784 Total: 
475 heroin-dependent cases 
309 controls 
0.121 
0.118 
0.083 
Hori (2001) 
[11] 
Japan 442 Total: 
241 cases with schizophrenia 
201 controls 
0.17 
0.18 
0.16 
Katsuragi 
(2001)[14] 
Japan 105 Total 0.252 
Yoshida 
(2001)[38] 
Japan 332 Total 0.161 
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Table 3: Reports investigating a link between DRD2 polymorphisms and smoking behaviors. Odds 
ratios were calculated as the odds of the reduced smoking behavior in the presence of the variant allele 
Author Geographic Area Variant Comparison Groups OR 
(95% CI) 
Interactions 
Comings 
(1996)[5] 
California, USA 
(limited to non-
Hispanic Caucasians) 
TaqIA Smokers = 312 
Controls = 714 
 
0.37 
(0.28-0.49) 
 
 
Current Smokers = 57 
Nonsmokers = 182 
0.464 
(0.251-0.857) 
Noble 
(1994)[25] 
Nevada and 
California, USA 
(Limited to non-
Hispanic Caucasians) 
TaqIA 
Current Smokers = 57 
Past Smokers = 115 
0.795 
(0.419-1.509) 
 
Singleton 
(1998)[28] 
England TaqIA Smokers = 104 
Nonsmokers = 117 
1.679 
(0.964-2.924) 
 
TaqIA Ever Smokers = 173 
Never Smokers = 107 
0.744 
(0.324-1.711) 
 Spitz 
(1998)[29] 
Texas, USA 
TaqIB Ever Smokers = 193 
Never Smokers = 76 
0.182 
(0.042-0.787) 
 
Lerman 
(1999)[21] 
USA Taq1A Smokers = 289 
Nonsmokers = 233 
0.830 
(0.580-1.188) 
Interaction with 
SLC6A3 genotype 
TaqIA Current Smokers = 72 
Former Smokers = 59 
0.988 
(0.473-2.066) 
 
TaqIA Current Smokers = 72 
Never Smokers = 87 
0.807 
(0.417-1.561) 
 
TaqIB Current Smokers = 60 
Former Smokers = 51 
0.565 
(0.265-1.204) 
 
Wu (2000) 
[36] 
Texas, USA 
(limited to African-
Americans and 
Mexican-Americans) 
TaqIB Current Smokers = 60 
Never Smokers = 80 
0.716 
(0.366-1.402) 
 
TaqIA  Current Smokers = 77 
Former Smokers = 57 
0.645 
(0.322-1.293) 
TaqIA Current Smokers = 77 
Never Smokers = 198 
2.25 
(1.314-3.857) 
 
-141C Ins/Del Current Smokers = 76 
Former Smokers = 57 
1.227 
(0.585-2.575) 
Yoshida 
(2001)[38] 
Japan 
-141C Ins/Del Current Smokers = 76 
Never Smokers = 194 
0.947 
(0.527-1.702) 
 
Lee 
(2002)[19] 
Korea 
Limited to 
individuals with 
schizophrenia 
TaqIA Smokers = 96 
Nonsmokers = 71 
0.850 
(0.425-1.700) 
Gender specific 
heterosis: Male 
heterozygotes 
more likely to 
smoke (sig), 
female 
heterozygotes less 
likely (ns) 
Lee 
(2003)[18] 
Korea Taq1A Smoker = 94 
Nonsmoker = 93 
0.937 
(0.506-1.736) 
 
Gender specific 
heterosis was 
reported 
Cinciripini 
(2004)[4] 
Texas, USA Taq1A 134 Smokers 
OR is for abstinence over 
several time points within 1 
year follow-up 
0.649 
(0.424-0.990) 
 
 
Johnstone 
(2004)[12] 
United Kingdom TaqIA  Current Smokers = 732 
Never Smokers = 243 
1.212 
(0.900-1.633) 
 
 
Swan 
(2005) 
[33] 
Washington, USA 
Limited to 
Caucasians 
Taq1A Continued Smokers = 276 
Quitters at 1 year = 140 
0.777 
(0.500-1.206) 
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Table 4: A summary of the frequencies of the SLC6A3 polymorphisms in Caucasians and the effect 
of the polymorphism 
Allele Frequency Nucleotide Change Effect 
SLC6A3-10 (WT) 73% 10-copy repeat None [26] 
Reduced concentration of transporter 
molecules on the surface of neurons [26, 35]SLC6A3-9 27% 9-copy repeat 
 
Table 5: Frequencies of the 9-repeat SLC6A3 allele reported in the literature 
Author Geographic Area N 
Frequency 
of 9-repeat 
allele 
Sabol (1999)[26] USA 1107 Total 0.267 
Lerman (1999) [21] USA 522 Total: 
444 Caucasians 
78 African Americans 
0.208 
0.193 
0.301 
Vandenbergh 
(2002)[35] 
Continental USA 579 Total: 
515 Whites 
31 Blacks 
0.247 
0.255 
0.194 
Erblich (2004)[7] New York, East Harlem, 
USA 
108 smokers – Predominately African 
American 
0.306 
Lerman (2003)[23] Washington, DC and New 
York, USA 
Limited to European 
Caucasian ancestry 
418 smokers 0.285 
Stein (2005)[30] Illinois, USA 47 children with attention deficit 
hyperactivity disorder (ADHD) 
0.362 
 
Van Dyck 
(2005)[34] 
Connecticut, USA 
Limited to European 
Americans 
96 Total 0.24 
Jorm (2000)[13] Australia 861 Caucasians 0.277 
Köhnke (2005) [16] Germany 318 Total: 
216 alcoholics 
102 controls 
0.42 
0.48 
0.32 
Galili-Weisstub 
(2005)[8] 
Israel 68 Total 0.46 
Simsek (2005) [27] Oman 110 Total 0.332 
Simsek (2005) [27] Oman  202 Total: 
92 children with ADHD 
110 healthy subjects 
0.327 
0.321 
0.332 
Cheon (2005) [3] Korea 11 children with ADHD 0.091 
Hong (2003) [10] Taiwan 210 Total: 
98 methamphetamine dependent cases 
112 controls 
0.083 
0.089 
0.078 
Lin (2003) [10] Taiwan 447 Total: 
193 cases with Parkinson’s Disease 
254 controls 
0.069 
0.083 
0.059 
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Table 6: Reports investigating a link between SLC6A3 polymorphisms and smoking behaviors. Odds 
ratios were calculated as the odds of the reduced smoking behavior in the presence of the variant (9-repeat) 
allele 
Author Geographic 
Area 
Comparison Groups OR 
(95% CI) 
Interactions 
593 Nonsmokers 
514 Current and Former 
Smokers 
0.89 
(0.70-1.12) 
Sabol (1999)[26] USA 
231 Former Smokers 
283 Current Smokers 
1.49 
(1.05-2.11) 
Non-
significant 
trend for 
interaction 
with DRD2 
TaqIA 
233 Smokers 
289 Controls (<100 
lifetime cigarettes) 
1.44 
(1.02-2.04) 
Caucasians only: 
237 Smokers 
207 Controls (<100 
lifetime cigarettes) 
1.40 
(0.96-2.03) 
Lerman (1999)[21] USA 
African-Americans only: 
52 Smokers 
26 Controls (<100 
lifetime cigarettes) 
1.19 
(0.44-3.24) 
Interaction 
with DRD2 
TaqIA 
452 Nonsmokers 
198 Current Smokers 
1.07 
(0.77-1.50) 
Jorm (2000)[13] Australia 
211 Former Smokers 
198 Current Smokers 
1.16 
(0.79-1.72) 
 
153 Former Smokers 
98 Current Smokers 
0.77 
(0.46-1.28) 
Vandenbergh 
(2002)[35] 
Continental 
USA (random 
digit dialing 
used) 
214 Never Smokers 
98 Current Smokers 
0.61 
(0.38-0.99) 
 
At the end of bupropion 
treatment: 
201 Abstinent 
217 Smoking 
1.16 
(0.79-1.70) 
Lerman (2003)[20] Washington, 
DC and New 
York, USA 
Limited to 
European 
Caucasian 
ancestry 
Six months following 
bupropion treatment: 
115 Abstinent 
303 Smoking 
1.15 
(0.75-1.77) 
DRD2 
TaqIA*SLC6A
3 at end of 
treatment and 
time*SLC6A3
*TaqIA  
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2.0  PREDICTORS OF SMOKING CESSATION ONE YEAR AFTER 
ENROLLMENT IN A LUNG SCREENING STUDY 
2.1 ABSTRACT 
Introduction 
Despite smoking prevention and cessation efforts, many people continue to smoke. Low-dose 
computed tomography (CT) screening programs for the early detection of lung cancer may 
provide a “teachable moment” for clinicians to discuss lung health and the benefits of smoking 
cessation with a large number of patients.  
 
Objective 
This cohort study attempts to identify differences between smokers who successfully quit 
smoking one year after entering a lung screening program and those who do not.  
 
Participants 
Participants are part of the Pittsburgh Lung Screening Study (PLuSS), a research-based low-dose 
CT screening program in which current and former cigarette smokers, ages 50 to 79 years, were 
recruited from the general population in the Pittsburgh area. Eligible members of the cohort must 
have smoked at least one-half pack per day for at least 25 years.  
 
Methods 
Questionnaire data from all baseline smokers who completed baseline and follow-up surveys 
were evaluated. Subjects (n=2046) were classified according to one-year quit status (Nonquitters, 
Unsuccessful Quitters, Successful Quitters) and to whether the CT necessitated a referral. 
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Relative risks were calculated, and multinomial logistic regression was used to identify the 
independent effect of the baseline CT result.   
 
Results 
The relative risk of being a Successful Quitter at one year after receiving a CT referral was 1.39 
(95% Confidence Interval (CI): 1.14-1.70). Even after controlling for marital status, gender, 
symptoms of lung disease, and pulmonary conditions, a CT referral was significantly related to 
quitting behavior (p<0.001). Relative to participants with CT results not resulting in a referral, 
participants who had CT results necessitating a referral were more often in the Unsuccessful 
Quitter group (OR: 1.43, 95% CI: 1.17-1.74, compared to Nonquitter) and to be in the Successful 
Quitter group (OR: 1.24, 95% CI: 0.96-1.61, compared to Unsuccessful Quitter).  
 
Conclusion 
This association supports the notion that CT screening can influence smoking behaviors, thereby 
creating a “teachable moment” for smoking interventions.. 
2.2 INTRODUCTION 
Despite ongoing smoking prevention and cessation efforts, many people continue to smoke.  
Almost half of all adults have smoked in their lifetime and, of those adults who have smoked, 
over half continue to smoke.[1] Although the prevalence of cigarette smoking has decreased over 
the past few decades in reaction to public health campaigns,[2] many smokers are still unable to 
quit. According to the National Health Interview Survey, 70% of smokers indicated that they 
wanted to quit; however, only 4.7% could abstain from smoking for at least three months.[1]  
Public health campaigns have improved awareness among past and current smokers that 
smoking increases the risk of lung cancer. We presume that personal knowledge of lung cancer 
risk attracts many smokers to screening programs. Although early attempts at lung cancer 
screening programs were discouraging, technological advances in screening modalities, 
specifically low-dose spiral computed tomography (CT) which has reduced both the level of 
radiation exposure and the amount of time required to complete the screening, have renewed 
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interest in lung cancer screening.[3, 4] Low-dose CT screening programs have been initiated 
worldwide.[5-9] In addition to the potential for early detection of disease, a possible benefit of 
mass screening with low-dose CT screening is a “teachable moment” for clinicians to discuss 
lung health and the benefits of smoking cessation with a large number of patients.[7, 10] 
Identifying characteristics of smokers who enter lung screening programs and differences 
between those smokers who do and do not quit after the screening will enable clinicians to take 
advantage of this “teachable moment” and apply interventions more effectively at screening 
visits. 
2.3 METHODS 
2.3.1 Population 
The current analysis focuses on participants in the Pittsburgh Lung Screening Study (PLuSS), a 
research-based low-dose CT screening program conducted as part of the University of Pittsburgh 
Lung Cancer SPORE program. PLuSS subjects were recruited through mass media (paid 
newspaper advertising and public service announcements), physician referral, and mass mailings. 
The cohort comprises current and former cigarette smokers between the ages of 50 and 79 years 
who were recruited between January, 2002 and April, 2005. Eligible members of the cohort must 
smoke or have smoked at least one-half pack per day for at least 25 years. Former smokers must 
have quit no more than 10 years prior to enrollment. 
2.3.2 Procedures 
As part of the PLuSS study protocol, eligible subjects were asked to complete a standardized, 
self-administered baseline survey. The survey was based on the Prostate, Lung, Colorectal and 
Ovarian (PLCO) Cancer Study baseline questionnaire and contained both multiple choice and 
open-ended questions regarding demographic characteristics, past and current smoking 
behaviors, family history of cancer, personal history of cancer, and personal history of other 
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smoking-related conditions and symptoms. The survey responses were visually edited and 
double entered. 
Clinical assessments included a baseline forced expiratory spirometry conducted and 
analyzed according to the American Thoracic Society and Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) Standards[11] and a low-dose spiral CT scan. Detailed 
results from the assessments were mailed to participants. Participants who received reports of 
suspicious nodules from their CT scan were invited to discuss the findings with the PLuSS 
physician. 
A brief telephone interview was to be conducted approximately one year after the 
baseline CT scan to determine if any changes in vital status, cancer status, or smoking status had 
occurred. For the current analysis, questionnaire data from all baseline smokers who completed 
both the baseline and the one-year follow-up survey were evaluated.  
Participants were classified as continuing smokers versus abstinent at one year based on 
their response to the annual study update question, “Are you currently smoking cigarettes?” For 
these analyses, participants who were abstinent at one year were restricted to those participants 
who remained abstinent for more than 30 days prior to the follow-up interview (Successful 
Quitters). A small number of participants (n=47) who were not smoking at the one year follow-
up but had quit for 30 days or fewer were excluded from the analyses. Continuing smokers were 
further divided into those who had not made any quit attempt in the follow-up interval 
(Nonquitters) and those who had made an attempt but were smoking at the time of the follow-up 
interview (Unsuccessful Quitters). One participant was excluded because quit status could not be 
determined from the information provided during the follow-up interview. 
2.3.3 Data Analysis 
Predictor variables included the following demographic variables: Gender (Male vs. Female), 
Age (by decade of life at baseline), Race/Ethnicity (White Non-Hispanic vs. other), Education 
(High School or less vs. other), and Marital Status (Married/living as Married vs. 
Divorced/Separated/Widowed vs. Never Married). Predictor variables also included Family 
History of Any Cancer (Yes vs. No), Family History of Lung Cancer (Yes vs. No) and Personal 
History Any Cancer Except Lung (Yes vs. No). Participants were asked if they had recently 
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experienced any of the following symptoms: Hemoptysis, Phlegm, Cough, Wheeze, Dyspnea, 
Edema, Weight Loss. In addition to considering these variables individually, two variables, 
Number of Symptoms (0 vs. 1 vs. 2 or more) and Any Symptoms (Yes vs. No), were derived 
from the symptom variables. Participants were asked if a doctor had told them that they had any 
of the following conditions: Bronchitis, Emphysema, Asthma, Heart Attack, Stroke. They were 
also asked if they had undergone a coronary artery bypass grafting (CABG) procedure. In 
addition to considering the condition and CABG variables individually, two variables, Number 
of Conditions (0 vs. 1 vs. 2 or more) and Any Conditions (Yes vs. No), were derived from 
individual items. Information from the baseline visit was used to construct the following 
variables: Referral required due to abnormal CT finding (Yes vs. No), Coronary Calcifications 
found at CT, emphysema found at CT (Yes vs. No), GOLD Stage (GOLD 0: At Risk vs. GOLD 
I/II : Mild/Moderate vs. GOLD III/IV : Moderate/Severe), Clean Bill of Health defined as no CT 
referral or and GOLD 0) . Time since the subject’s last chest x-ray or CT scan was also evaluated 
(Less than 1 year ago vs. 1 to 2 years ago vs. 2 to 3 years ago vs. More than 3 years ago vs. 
Never). Predictor variables related to smoking history included Start Age (less than 18 vs. 18 and 
older), Start Age (Continuous), Baseline Cigarettes Per Day (Less than 20 vs. 20 to 39 vs. 40 or 
more), and Smoking Duration (Continuous).  
Differences involving the predictor variables were evaluated individually according to 
smoking behavior. We used chi-squared tests and analysis of variance to evaluate the association 
between each risk factor and smoking behavior one year later. The focus of subsequent 
multivariate analyses was to develop a parsimonious model that described the independent 
contribution of CT referral on subsequent smoking behavior while controlling for factors that 
had a material effect on the relationship between CT referral and smoking behavior. Using 
multinomial logistic regression,[12] we evaluated the independent contribution of all selected 
predictors of behavior. The advantage of using this method is that the impact of the predictors on 
all three outcomes can be evaluated simultaneously. [12] The log-likelihood ratio test was used 
to evaluate the statistical significance of main effects and two-way interactions. If a variable had 
no main effect or material effect on the association between CT referral and smoking it was 
dropped from the model. Using all variables except CT referral we tried to obtain the best-fit 
model. CT referral was then added to the model. 
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2.4 RESULTS 
Of the 3755 PLuSS participants, 3411 completed the one-year follow-up prior to this analysis. 
Approximately half of the participants who completed the follow-up were male (50.9%) and 
most were Caucasian (92.9%). The average age at baseline was 59.7 years. Participants had been 
smoking for an average of 41.2 years. CT referral was recommended for 1609 (42.8%) 
participants. Primarily the referrals were requested due to the presence of small non-calcified 
lung nodules that created suspicion for some level of lung cancer; however, other abnormalities 
involving the airway or heart were also cause for referral. Among the 2275 (60.6%) smokers at 
baseline, over half (57.7%) smoked between one and two packs of cigarettes per day, and few 
(6.6%) smoked more than two packs per day. The one-year assessment was completed at a 
median of 349 days (interquartile range = 24 days). 
Expired air carbon monoxide measures were used to validate self-reported smoking status 
in a convenience sample of 228 PLuSS participants who returned for a follow-up visit between 
August, 2005 and January, 2006. One participant took the test on two separate occasions 
approximately one month apart; thus, a total of 229 readings are reported. Participants were 
asked their smoking status prior to taking the test. A total of 108 participants indicated that they 
were not smoking, and 121 indicated that they were smoking.  Of the 108 participants who 
reported not smoking, 13 (12%) tested positive for smoking. Of the 121 participants who 
reported that they were smoking, 9 (7%) tested negative for smoking.  
Figure 1 classifies participants (N=3755) in the source population (PLuSS) according to 
the factors (smoking status at baseline and one year later) used to construct the comparison 
groups of interest (Successful Quitters, Unsuccessful Quitters, Nonquitters). Among the 2046 
baseline smokers for whom one year quit status is available, 59.5% [(370+847)x100/2046] had 
made a quit attempt and 15.7% [321x100/2046] were abstinent for more than 30 days prior to 
and at the time of the follow-up interview. The final sample for this analysis was comprised of 
1997 participants: 829 in the Nonquitter group, 847 in the Unsuccessful Quitter group, and 321 
in the Successful Quitter group. Baseline variables of baseline smokers who completed the one-
year follow-up (N=2046) were compared to those who did not complete follow-up (N=229). Of 
the 229 who did not complete the follow-up telephone questionnaire, 77 (33.6%) were not 
eligible because they had not completed the baseline CT scan, 71 (31.0%) were not eligible 
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because their baseline CT scan was less than one year prior to this analysis, 12 (5.2%) were 
deceased, 2 (0.9%) refused to complete the follow-up, and 67 (29.3%) could not be reached. 
Baseline smokers who completed the follow-up were more likely to be older (p=0.03), white 
non-Hispanic (p=0.02), educated beyond high school (p<0.01), and married (p<0.01).  
The primary study results appear in table 7. The Successful Quitter group was comprised 
of 18.9% of the participants receiving a CT referral and 13.5 % of the participants not receiving a 
CT referral (Relative Risk: 1.39, 95% Confidence Interval (CI): 1.14 – 1.70). See table 7. We 
combined the Successful Quitter and Unsuccessful Quitter groups to calculate the relative risk of 
making a quit attempt in the one-year follow-up interval given a CT referral. When the 
Successful Quitter and Unsuccessful Quitter groups were combined, 64.0 % (18.9% + 45.1%) of 
participants receiving a CT referral and 54.3% (13.5% + 40.8%) of participants not receiving a 
CT referral reported making a quit attempt in the one-year follow-up interval (Relative Risk: 
1.18, 95% CI: 1.10 – 1.27). Table 7 also shows other factors associated with the outcomes of 
interest (gender, race, marital status, smoking intensity, number of symptoms and number of 
conditions).  
The list of candidate variables for use in the logistic regression analysis was restricted by 
identifying those variables that best represented each conceptual domain of interest (eg. 
symptoms) and by giving preference to variables with the best distributional properties and the 
strongest association with the smoking outcome. For example, Number of Symptoms was 
selected because it was more informative and showed a stronger association with smoking 
behavior than the dichotomous variable Any Symptoms. Number of Symptoms also served as a 
summary variable for the individual symptom variables, which varied in their distributional 
properties and strength of association. CT screening referral showed a significant association 
with smoking behavior at one year (p<0.001) with a higher proportion of participants referred 
because of an abnormal CT scan in both the Successful Quitter and Unsuccessful Quitter groups 
than those not referred. The lightest smokers appeared to have more success in quitting than 
heavier smokers (p=0.050). 
For the final model, we considered the impact of gender, marital group, number of 
symptoms, number of conditions, CT referral, and baseline cigarettes per day. Marital status was 
missing in three participants; therefore, these participants were excluded from the regression 
analysis. The variables decade of age and baseline cigarettes per day were not significant as main 
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effects and did not impact the relationship between CT referral and quit attempt status; hence, 
they were excluded from the final model. The high proportion of white non-Hispanic participants 
makes comparisons by race difficult. Therefore, once a final model was established it was rerun 
in only white non-Hispanic participants to determine if race had an impact on the findings. 
Significant interaction terms included marital group by number of conditions and gender by 
number of symptoms. Thus, the final model included gender, marital status, number of 
symptoms, number of conditions, CT referral and the interaction terms marital group by number 
of conditions and gender by number of symptoms.  
Overall, controlling for gender, marital status, number of symptoms and conditions, and 
interaction terms, CT referral is significantly related to quitting behaviors (p<0.001). In 
comparing individuals who receive a referral after their CT scans versus those who do not, the 
odds ratio for having being in the Unsuccessful Quitter group versus Nonquitter group at the one 
year of follow-up is 1.43 (95% Confidence Interval (CI): 1.18-1.79), and the odds ratio for being 
in the Successful Quitter group versus being in the Unsuccessful Quitter group is 1.24 (95% CI: 
0.96-1.61). CT referral remains highly significant when the model is restricted to white non-
Hispanic participants. Restricting the Unsuccessful Quitter group to only those participants who 
had made a serious attempt to quit (lasting more than seven days), we repeated the analysis and 
found associations between quit attempt status and CT referral that were similar to those in the 
entire group (p<0.01, Unsuccessful Quitter versus Nonquitter OR: 1.50, 95% CI: 1.20-1.88; 
Successful Quitter versus Unsuccessful Quitter OR: 1.18, 95% CI: 0.89-1.56). We then 
conducted binary logistic regression to determine if similar relationships were apparent when 
comparing the NonQuitter group to those who did attempt to quit (combining the Successful 
Quitter and Unsuccessful Quitter groups) and found that participants who had a CT referral were 
significantly more likely quit (Successfully or unsuccessfully) than those who did not have a CT 
referral (OR: 1.52, 95% CI: 1.26-1.82). However, when participants in the Unsuccessful Quitter 
and the Successful groups were compared, CT referral was no longer significant (OR: 1.22, 95% 
CI: 0.94-1.59).  
Additional analyses were conducted to further investigate the contribution of interaction 
terms to the model. The results are displayed in figures 2 and 3. In examining the role of marital 
status and conditions on quitting behaviors, number of conditions only had a significant impact 
on being in the Unsuccessful Quitter group versus the Nonquitter group in participants who were 
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formerly married (divorced/separated/widowed). Participants who were formerly married were 
more likely to be in the Unsuccessful Quitter group if they had at least one condition versus 
none. In general, the trend among all three marital groups appeared to be that having more 
symptoms increased the odds of being in the Unsuccessful Quitter group. Number of conditions 
only had a significant impact on having a being in the Successful Quitter group versus being in 
the Unsuccessful Quitter group in participants who were married. Married participants were less 
likely to be in the Successful Quitter group if they had two or more conditions versus no 
conditions. The gender by symptoms interaction term followed a similar pattern. Men were 
significantly more likely to be in the Unsuccessful Quitter group when they had symptoms. Both 
men and women seemed to be less likely to be in the Successful Quitter group when they had 
two or more symptoms; however, these odds ratios were not significant. 
2.5 DISCUSSION 
The present study supports the hypothesis that lung screening provides practitioners with a 
“teachable moment” to discuss smoking cessation with their patients.  
Previous reports on the impact of lung screening on smoking behavior have been 
inconsistent. Ostroff et al. surveyed participants in the Early Lung Cancer Action Program 
(ELCAP) who were baseline smokers to determine if participation in the program influenced 
their smoking behaviors or their thoughts about smoking. A large number of participants 
reported quitting (23%) or cutting back (27%). Few factors appeared to differentiate those who 
quit or reduced smoking from those who did not change or increased their smoking. Older 
subjects were less likely to quit and subjects with an abnormal CT finding, particularly women, 
were more likely to quit.[6] Cox et al. conducted a similar investigation of baseline smokers and 
former smokers who enrolled in a low-dose CT lung cancer screening study at the Mayo Clinic. 
This study also found abstinence rates that were higher than expected (17.9% observed versus 5 
to 7% expected in the general population). Self-reported abstinence was biochemically validated, 
and 98% of the reports were accurate. Subjects with abnormal pulmonary function test findings 
were more likely to quit at one year. However, CT findings did not appear to influence quitting 
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at one year. Also contrary to the Ostroff findings, in a univariate analysis of baseline smokers, 
older age positively predicted abstinence. This was not significant in a multivariate analysis.[7] 
The current study has a quit rate similar to that found in the Mayo Clinic study even 
when the participants who quit for less than 30 days are excluded (15.7%). Thus, all three studies 
reported higher than expected cessation rates.[13] The current study shows that individuals who 
received CT referral were more likely to try to quit than those who did not. Although we cannot 
disregard the possibility that this difference is due to a reduction in cessation among those who 
did not receive a referral, the higher than expected cessation rates overall lead us to believe that 
the CT referrals promoted smoking cessation. However, these differences highlight the need for 
clinicians to not only take advantage of the teachable moment among patients with abnormal 
results but also to consider how to create a teachable moment when conveying normal test 
results. Because PLuSS participants were often counseled in smoking cessation after receiving 
an abnormal result, we cannot differentiate between the consequences of receiving an abnormal 
result from the consequences of the counseling that occurred from the referral. Differences in 
how abnormal CT results are handled may explain the differences in the results across the three 
studies. The Mayo Clinic study that showed no association between abnormal CT results and 
smoking cessation did find an association with abnormal pulmonary function test findings. Thus, 
in all three studies abnormal screening results were associated with cessation rates. This 
highlights the potential of various modes of lung screening to provide teachable moments for 
smoking cessation. 
This study found interactions between marital status and number of conditions and 
between gender and number of symptoms. The significance of these interactions is unclear. They 
may be spurious findings due to multiple testing during the model building procedure. They may 
relate to selection bias. For example, individuals with multiple symptoms or conditions may have 
been pressured to quit smoking more than those without symptoms or conditions. Because this 
study was limited to baseline smokers, only those participants with multiple conditions or 
symptoms who continued to smoke despite this pressure would have been included in this 
analysis. The added advice provided by PLuSS may have had minimal impact on these 
participants. Conversely, for a participant who was not under much pressure to quit because of 
otherwise good health, the advice provided by PLuSS may have had a greater impact.  
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The baseline predictor variables appeared to have a stronger effect on making a quit 
attempt than on being abstinent at one year. This, along with the high number of participants who 
made quit attempts but were smoking again by the one year follow-up, highlights the lack of 
effective quit strategies. Teachable moments may help clinicians provide motivation for 
participants to quit smoking but they may not ultimately help smokers quit smoking. This finding 
also may suggest that different factors, such as genetics, may play a role in successfully quitting. 
Age, smoking duration, and smoking intensity were all eligibility criteria for entry into 
PLuSS; thus, the amount of variation in these criteria was limited. If greater variation in these 
factors was present in the study population, we may have found significant associations with 
smoking behavior.  
Self-selection bias could have impacted the one-year follow-up results if a significant 
number of participants chose not to complete the one year follow-up questionnaire. Of the 229 
who did not complete the follow-up 160 (70%) could not complete the follow-up because they 
were not eligible or they were deceased. Thus, of the 2115 who could have completed the 
follow-up, 97% did complete it. Differences in a few sociodemographic variables existed 
between participants who completed the one-year follow-up and those who did not; however, no 
differences existed in CT referral rates between the two groups (p=0.758). Therefore, self-
selection bias would seem to have very little effect on the results of this study.  
Because the study sample was predominantly Caucasian, generalizations regarding 
differences in behavior based on race could not be made. However, these data do show an 
interesting trend. As shown in table 7, Non-Caucasians were more likely to have an unsuccessful 
quit attempt, but Caucasians were more likely to succeed in quitting. Non-Caucasians in this 
sample were predominately African-American (91%), and previous reports have highlighted 
disparities in smoking cessation between Caucasians and African-Americans.[14] If verified in 
future studies, this finding could indicate that current smoking cessation treatment strategies 
need to be modified to suit the needs of Non-Caucasians.  
Although we estimated the validity of self-reported smoking status for a subset of the 
PLuSS population, we were unable to measure the validity of self-reported smoking status in the 
entire sample at their one-year follow-up visit. The available data indicate that 12% of smokers 
may have misreported their smoking status. The rates of reporting error do not differ 
 31 
significantly by CT referral group. Thus, misclassification may have influenced the intensity, but 
not the direction of the effect of an abnormal CT finding on smoking status.  
Due to the inconsistencies of currently available reports of the impact of lung screening 
on smoking behavior, additional studies are needed. If future studies support the hypothesis that 
lung screening promotes smoking cessation then cost effectiveness analyses should consider not 
only the early detection of lung cancers with screening, but also the prevention of lung disease 
with increased smoking cessation. 
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Figure 1: Smoking status of participants at baseline and follow-up 
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Table 7: Subjects, number (N) and percentage (%), according to baseline personal characteristic, 
and cigarette smoking behavior on follow-up, stratified according to baseline personal characteristic 
Nonquitter
Unsuccessful 
Quitter
Successful 
Quitter
Characteristic N % (N=788) (N=817) (N=305) p-value
Overall 1,910 100.0 41.3 42.8 16.0
Demographic
Gender 0.006
men 931 48.7 44.9 39.6 15.5
women 979 51.3 37.8 45.8 16.4
Age (years) 0.188
50-59 1,178 61.7 43.0 42.0 14.9
60-69 565 29.6 39.1 44.1 16.8
70-79 167 8.7 35.9 43.7 20.4
Race
white 1,752 91.7 42.4 41.3 16.4 0.000
non-white 137 7.2 28.5 60.6 10.9
Education
post high school 1,446 75.7 41.5 42.5 16.0 0.921
no greater than high school 464 24.3 40.5 43.5 15.9
Marital Status
Married 1,200 62.8 43.7 40.0 16.3 0.010
Divorced/Separated/Widowed 568 29.7 35.7 48.4 15.8
Never Married 139 7.3 42.4 44.6 12.9
Baseline smoking behavior
Duration (years)
<46 1,352 70.8 42.2 42.5 15.2 0.261
46+ 558 29.2 38.9 43.4 17.7
Intensity (cigarettes per day)
<20 663 34.7 38.0 42.7 19.3 0.042
20-39 1,124 58.8 43.1 42.6 14.3
40+ 123 6.4 42.3 44.7 13.0
Medical factors
Number of symptoms
0 292 15.3 44.2 36.6 19.2 0.001
1 414 21.7 39.9 39.4 20.8
2+ 1,204 63.0 41.0 45.4 13.5
Number of conditions
0 1,283 67.2 42.6 40.8 16.6 0.013
1 361 18.9 41.3 42.4 16.3
2+ 266 13.9 35.0 52.6 12.4
CT screening referral
yes 873 45.7 36.0 45.1 18.9 0.000
no 1,037 54.3 45.7 40.8 13.5
Smoking behavior on Follow-up (%)
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Figure 2: Odds of advancing on the cessation continuum given marital status and number of 
conditions (no conditions serves as the comparison group) 
 
0
1
2
3
4
O
dd
s 
ra
tio
One Symptom
2+ Symptoms
WomenMen WomenMen
Successful Quitter vs. 
Unsuccessful Quitter
Unsuccessful Quitter
vs. Nonquitter  
Figure 3: Odds of advancing on the cessation continuum given gender and number of symptoms (no 
symptoms serves as the comparison group) 
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3.0  SMOKING AND THE DOPAMINE PATHWAY: VARIANTS OF THE 
DOPAMINE RECEPTOR 2 (DRD2) GENE 
3.1 ABSTRACT 
Introduction 
Smoking cessation strategies continue to have disappointing results. By determining the 
interindividual genetic differences that influence smoking behaviors, we may be able to develop 
tailored strategies that increase the likelihood of successful cessation. 
 
Objective 
This study attempts to determine genetic influences on the relationship between the dopamine 
pathway and smoking cessation by examining associations with the DRD2 variants TaqIA (A2 
vs. A1), TaqIB (B2 vs. B1), C957T (C vs. T), and –141C Ins/Del (C vs. Del). 
 
Participants 
Participants are part of the Pittsburgh Lung Screening Study (PLuSS), a research based low-dose 
CT screening program containing current and former cigarette smokers, ages 50 to 79 years, 
recruited from the general population in the Pittsburgh area. Eligible members of the cohort must 
have smoked at least one-half pack per day for at least 25 years.  
 
Methods 
Questionnaire data from all baseline smokers who completed baseline and follow-up surveys 
were evaluated. Subjects were classified according to one-year smoking status (Not Abstinent at 
one year, Abstinent at one year). All individuals in the Abstinent group were included in the 
genotype analysis. Individuals in the Not Abstinent group were frequency matched by gender, 
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decade of age, and time of enrollment (three month intervals) in a three to one ratio to the 
Abstinent group. Logistic regression was used to identify the effect of individual genotypes on 
abstinence at one year.  
 
Results  
After controlling for the matching variables and other genotypes, the DRD2 TaqIA 
polymorphism was significantly associated with being abstinent at one year (p=0.01). Compared 
to participants who had the homozygous wild type TaqIA genotype (A2A2), participants who 
carried at least one variant allele (A1) were less likely to quit (Odds Ratio: 0.47, 95% CI: 0.24-
0.94).  
 
Conclusion  
This association supports the hypothesis that genetic variation in the dopamine pathway 
influences smoking cessation. 
3.2 INTRODUCTION 
The dopamine pathway is a major reward pathway implicated in addiction to nicotine and other 
addictive drugs. The effectiveness of bupropion, an antidepressant that acts on the dopamine 
pathway and that helps smokers quit, supports the hypothesis that genetic variation along the 
dopamine pathway may cause differences in smoking behaviors including cessation. Among the 
five dopamine receptors, DRD2 received the most attention initially because of the proposed 
association between the TaqIA restriction fragment length polymorphism (RFLP) on the DRD2 
gene, located on chromosome 11q23, and alcoholism. This has led to DRD2 research for various 
addictions and disorders, including nicotine addiction.  
The TaqIA restriction fragment polymorphism (RFLP) occurs 10 kilobases (kb) into the 
3’ untranslated region of the DRD2 gene and results from a cytosine (C) to thymine (T) single 
nucleotide polymorphism (SNP). In addition to the initial association studies linking this variant 
to alcoholism, a link between this variant and reduced receptor density has been reported. This 
combination of findings has contributed to this variant being the most studied DRD2 allele. A2 is 
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the wild type allele, and A1 is the variant. Reported frequencies of the A1 allele in Caucasians 
range from 16% to 41% with most reports ranging between 19% and 28%. Studies investigating 
the relationship between the TaqIA variant and smoking behaviors have had mixed results. Most 
studies have found increased odds of smoking with the A1 allele; however, few of these studies 
have reached statistical significance.[1-3] Many studies have investigated the relationship 
between the presence of any variant allele and smoking behaviors; however, two studies from the 
same investigators in Korea found evidence of gender-specific heterosis when TaqIA was 
evaluated as a three level variable.[4, 5]   
The TaqIB RFLP is an adenine (A) to guanine (G) SNP. Unlike TaqIA, no association 
between receptor density and TaqIB has been reported; however, the TaqIB RFLP has been the 
subject of increased study because it is closer to the coding regions of the gene than TaqIA. 
Among Caucasians, the frequency of this allele has been reported as 16%. [6] In two reports that 
investigated the relationship between this variant and smoking, the TaqIB variant allele (B1) 
appeared to be positively related to smoking; however, this only reached statistical significance 
in specific subject groups. In one report, control participants and cancer cases were evaluated 
separately, and statistical significance was reached only in controls. Similarly, in the other report, 
Mexican-American and African-American participants were evaluated separately, and statistical 
significance was reached only in the Mexican-American participants. [3, 6] 
C957T is a SNP which results in a synonymous amino acid change in the DRD2 enzyme. 
In a study evaluating the impact on mRNA stability, the presence of the T allele (variant) 
resulted in a decreased half-life of mRNA. The frequency of the T allele in a European-American 
population of 94 subjects was 57%.[7] The National Center for Biotechnology Information’s 
dbSNP database cites a frequency of the T allele among Caucasians as 48%.[8] Although most of 
the research on this variant has focused on functionality of the variant rather than potential 
associations with disease, in a recent report Lerman et al. investigated potential associations 
between this SNP and smoking cessation pharmacotherapy in two clinical trials. The first trial 
compared bupropion therapy to placebo in 414 participants. No interaction with treatment group 
was observed, but in multivariate analyses, participants with the CC or CT genotypes were less 
likely than those with the TT genotype to be abstinent at six months post-treatment with 
bupropion or placebo (p=0.05). No statistically significant association was observed in the 
univariate analysis. The second trial compared two forms of nicotine replacement therapy, 
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transdermal nicotine and nicotine spray, in 368 participants. Participants with the CC or CT 
genotypes were also less likely than those with the TT genotype to be abstinent at the end of 
treatment (p=0.03), but no interaction was found with nicotine therapy type.[9] 
The –141C Insertion/Deletion (–141C Ins/Del) variant is a functional polymorphism that 
results in the deletion of a single cytosine from a pair of cytosines in the promoter region of 
DRD2.[10, 11] The presence of this variant has been shown to reduce promoter activity by more 
than half.[11] In German Caucasians, the frequency of deletion was reported to be 9.5%.[12] 
Among a group of alcohol and drug dependent Caucasians and their parents, the allele 
frequencies for a deletion ranged from 11% to 16%.[11] We could find only two reports that 
investigated the relationship between this variant and smoking behaviors. In one, no relationship 
between this variant and smoking status was observed.[13] In the second, Lerman et al. 
examined potential associations between this SNP and pharmacotherapy (bupropion therapy and 
nicotine replacement therapy) as described above for C957T.  An interaction between treatment 
group and –141C Ins/Del genotype was observed in both trials. In the placebo group of the 
bupropion trial participants with the CC genotype were less likely to quit, but in the bupropion 
group participants with the any deletion were less likely to quit (p=0.01 at the end of treatment, 
p=0.08 at 6 months). Overall, at the end of treatment participants with any deletion were more 
likely to be abstinent. No interaction between genotype and treatment group were observed.[9] 
Figure 4 shows the location and dbSNP identification numbers of the four selected 
variants along the DRD2 gene. The purpose of this investigation was to determine if these 
variants, alone or in combination, are associated with smoking cessation in participants in a lung 
screening study. 
3.3 METHODS 
3.3.1 Population 
The current study focuses on participants in the Pittsburgh Lung Screening Study (PLuSS), a 
research-based low-dose computed tomography (CT) screening program conducted as part of the 
University of Pittsburgh Lung Cancer SPORE program. PLuSS participants, recruited between 
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January, 2002 and April, 2005, are current and former cigarette smokers between the ages of 50 
and 79 years who smoke or smoked at least one-half pack per day for at least 25 years. At 
baseline, participants completed a questionnaire and assessment that included a CT scan and 
pulmonary function test. At approximately one year after their baseline CT scan, participants 
completed the annual study update that included a repeat CT scan and a brief telephone 
questionnaire to determine if any changes in vital status, cancer status, or smoking status had 
occurred.  
Expired air carbon monoxide measures were used to validate self-reported smoking 
abstinence in a subset of 228 PLuSS participants who returned for a follow-up visit between 
August, 2005 and January, 2006. A total of 229 readings were compared to self-reported 
smoking abstinence. Participants were asked their smoking status prior to taking the test. Using 
the recommended cutoff of 8 parts per million or higher as a positive test for smoking[14], we 
found that 13 (12%) of the 108 participants who reported not smoking tested positive for 
smoking and 9 (7%) of the 121 participants who reported that they were smoking tested negative.  
Genotyping analyses were conducted in a subset of PLuSS participants who were 
smoking at baseline and had provided information regarding their smoking status during the 
annual study update at the time of subset selection. Participants who had lung cancer diagnosed 
in the one-year follow-up interval were excluded. Because the PLuSS population was over 90% 
Caucasian, the genotyping subset was limited to Caucasians.  
Participants were classified as Abstinent versus Not Abstinent at one year based on their 
response to the annual study update question, “Are you currently smoking cigarettes?” The 
Abstinent at One Year group was further restricted to those participants who remained abstinent 
for more than 30 days prior to the follow-up telephone questionnaire. For the primary case-
control analysis, participants who were in the Not Abstinent group served as the control group 
and the Abstinent group served as the case group. Subset selection occurred at two time points 
based on the status of the PLuSS database: October, 2004 and July, 2005. All individuals in the 
Abstinent group were included in the subset. Those in the Not Abstinent group were frequency 
matched to those in the Abstinent at group by gender, decade of age, and time of enrollment (in 
three month intervals). Within each stratum (cross of gender, decade of age, and time of 
enrollment), three individuals who were not abstinent at one year were selected for each 
individual in the Abstinent group. In cases where a stratum did not contain enough Not Abstinent 
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participants, Not Abstinent participants were selected from an adjacent time of enrollment or 
decade of age stratum. This modification of the matching strategy was only necessary for the 
October, 2004, subset. Of the 900 specimens that were requested (225 Abstinent at one year, 675 
Not Abstinent at one year), 881 had blood specimens available and were successfully genotyped 
for TaqIA and TaqIB (219 Abstinent at One Year, 662 smokers). C957T results could not be 
obtained for 13 additional participants, and –141C Ins/Del results could not be obtained for one 
additional participant. In the final data set, no significant case-control group differences in 
gender, decade of age, or time of enrollment between individuals who were abstinent at one year 
and smokers was observed. 
3.3.2 Genotyping Procedures 
The DRD2 (TaqIA, TaqIB, C957T, -141C Ins/Del) polymorphisms were genotyped by TaqMan 
allele discrimination assays using the Applied Biosystems 7700 system (Applied Biosystems, 
Foster City, CA). These assays were designed using the Applied Biosystems Primer express 
software, version 1.5. All reactions were performed using 1X Universal Master mix, 200nM VIC 
or FAM labeled probes and 20ng of genomic DNA. For DRD2 TaqIA and TaqIB site screening, 
600 nM PCR primer concentrations were used. For the C957T and -141C Ins/Del 
polymorphisms, 900 nM PCR primer concentrations were used. Thermal cycling was initiated 
with a pre-PCR step, 2 min incubation at 50° C, followed by 10 min at 95° C, and then by 49 
cycles of 15 sec at 95° C and 1 min at 67° C (TaqIA), 59° C (TaqIB), 64° C (C957T) or 55° C (-
141C Ins/Del). Positive and negative PCR controls were included with each amplification 
reaction. An additional 10% of samples were repeated to verify the reproducibility of the assay. 
All results were interpreted independently by two laboratory personnel who were blinded to the 
case-control status of participants. In the event of a discrepancy, the genotyping assay was 
repeated until concordance was reached. 
 42 
3.3.3 Data Analysis 
Matching variables included gender (male vs. female), age (by decade of life at baseline), and 
enrollment date (by quarter). Other potential risk factors included sociodemographic variables, 
health-related variables, and smoking history variables. Sociodemographic variables were 
Education (high school or less vs. other), and Marital Status (married/living as married vs. 
divorced/separated/widowed vs. never married). Health-related variables were Family History of 
Any Cancer (yes vs. no), Family History of Lung Cancer (yes vs. no), Personal History of Any 
Cancer Except Lung (yes vs. no), Number of Symptoms of lung disease (0 vs. 1 vs. 2 or more), 
Number of Health Conditions (0 vs. 1 vs. 2 or more), and Referral required due to abnormal CT 
finding (yes vs. no). Participants were asked if they had recently experienced any of the 
following symptoms: Hemoptysis, Phlegm, Cough, Wheeze, Dyspnea, Edema, Weight Loss. The 
variable Number of Symptoms was derived from the individual symptom variables. Participants 
were asked if a doctor had told them that they had any of the following conditions: Bronchitis, 
Emphysema, Asthma, Heart Attack, Stroke. They were also asked if they had undergone a 
coronary artery bypass grafting (CABG) procedure. The Number of Conditions variable was 
derived from the individual items. Smoking history variables included Start Age (continuous), 
Baseline Cigarettes Per Day (less than 20 vs. 20 to 39 vs. 40 or more), Smoking Duration 
(continuous) and Smoking Duration (less than 46 years or 46 years or more). The genetic 
variables were examined by genotype (TaqIA: A1A1 vs. A1A2 vs. A2A2; TaqIB: B1B1 vs. B1B2 
vs. B2B2; C957T: CC vs. CT vs. TT; -141C Ins/Del: CC vs. C- vs. --) and by presence or absence 
of the variant allele. 
Hardy-Weinberg equilibrium was assessed in the control population for each variant. The 
relationships between risk factors, genetic variables and one-year smoking abstinence were 
initially assessed using univariate analysis techniques (chi-squared tests, t-tests, and Fisher’s 
exact tests as appropriate). The focus of the analysis was to determine the impact of genotype on 
smoking cessation, so univariate tests also included an evaluation of relationships between 
genetic variables and other risk factors in the control population (continuing smokers). Crude 
odds ratios were calculated to initially evaluate the contribution of the genetic variables to 
smoking cessation. We used logistic regression to calculate adjusted odds ratios for each genetic 
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variable by controlling for matching variables. Logistic regression was used to evaluate a full 
model that included all of the genetic variables.  
A second model was constructed that included non-genetic variables. Variables that were 
statistically significantly associated with smoking abstinence in the univariate analysis were 
included in the model building analysis as were variables that showed associations with smoking 
abstinence in a previous evaluation of the PLuSS population. The log-likelihood ratio test was 
used to evaluate the statistical significance of the main effects and two-way interactions. Once 
the best fitting base model was established without the genetic variables, the genetic variables 
were added.  
Exploratory analysis of DRD2 haplotypes was conducted by first constructing haplotypes 
using the PHASE program (Version 2.1). The case-control permutation test in PHASE was used 
to determine if significant differences existed in the haplotype frequencies between the Abstinent 
at One Year group and the continuing smokers. Chi-square tests were then used to evaluate the 
association of each of the five most frequent haplotypes with quitting. The odds of quitting given 
the presence of each of the five most frequent haplotypes were also calculated. 
3.4 RESULTS 
The allele frequencies for each gene are displayed in table 8 and are consistent with frequencies 
reported in the literature for Caucasians. TaqIA and C957T were in Hardy-Weinberg equilibrium 
while the homozygous variant genotype appeared to be underrepresented in the control 
population for TaqIB and –141C Ins/Del. Results of the univariate analysis for selected variables 
are displayed in table 9. Number of symptoms at baseline (p=0.006), TaqIA genotype (p=0.001) 
and presence of TaqIA variant allele (p=0.029) were the only predictor variables that were 
significantly associated with smoking behavior at one year. The direction of the TaqIA and 
TaqIB genotypes in relation to smoking appears to follow a pattern of heterosis, with 
heterozygous being less likely to quit smoking; however, the number of individuals with the 
homozygous variant genotypes were very small. 
Few variables were associated with genotype as shown in tables 10 through 13. Gender 
differences were significant for TaqIB and showed a trend toward significance for C957T, with 
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males being over represented in the group with a variant allele for TaqIB and in the homozygous 
wild type group for –141C Ins/Del. Due to small cell sizes, time of enrollment was grouped in 
six month rather than three month intervals. A significant association was found between TaqIB 
genotypes and CT screening referral (p=0.043). Participants with the B1 allele were more likely 
to have a CT scan that necessitated a referral. 
Table 14 shows the odds ratios for each variant. TaqIA had a statistically significant 
relationship with smoking behavior even after adjusting for matching variables and other genetic 
variables (p=0.03). Compared to participants with the A2A2 genotype (homozygous wild type) 
participants carrying a variant allele were less likely to be abstinent at one year. No other SNPs 
were significant when either the crude or adjusted odds ratios were calculated. Similarly, based 
on analyses described below, number of symptoms was added to the model to determine if it 
affected the relationship between TaqIA and smoking abstinence. The association between TaqIA 
and smoking abstinence did not change when number of symptoms was added to the model (data 
not shown). 
For the regression analysis that included non-genetic variables, the matching variables 
(gender, decade of age, and time of enrollment) were initially forced into the model. No two-way 
interactions of the matching variables were significant. Number of symptoms, baseline packs per 
day, and CT referral were then entered into the model and two-way interactions were assessed. 
Number of symptoms was significant; baseline packs per day, CT referral and interaction terms 
were not significant. Thus, the base model contained the matching variables and number of 
symptoms. TaqIA and related interaction terms were entered into the model. TaqIA was 
significant as a main effect. No two-way interactions were significant. TaqIB and related 
interaction terms were then added to the base model. TaqIB was not significant as a main effect 
or as part of two-way interactions. C957T and interaction terms were entered into the base model 
limited to the 653 participants with complete data for this variant. The C957T by age interaction 
term was significant. This remained true when TaqIA was added to the model. The –141C 
Ins/Del genotype was assessed in the 880 participants who had complete data for this variant. 
The –141C Ins/Del genotype and interaction terms were not significant when they were added to 
the base model. (Data not shown.) 
We repeated the model building exercise limiting the comparison to the 323 control 
participants who reported trying to quit during the one year follow-up versus the 214 cases for 
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whom the complete genotype data were available. Number of symptoms, C957T, and C957T by 
age remained statistically significant (p<0.05 for all). We then compared the participants who 
tried to quit (n=537) to the control participants who reported that they did not try to quit (n=330). 
The best fitting model comparing these two groups did not contain any genetic variables but 
included only the CT by age interaction term. (Data not shown.) 
To further examine the C957T by age interaction term, the contribution of C957T to 
smoking cessation was examined separately for each decade of age (table 15). The chi-square 
test was significant at p<0.05 only for participants age 50 to 59. The adjusted odds ratio for this 
group was also statistically significant. In this age group participants carrying a variant allele 
were more likely to be abstinent at one year (OR: 2.13, 95% CI: 1.18-3.83). Although age is 
significantly associated with smoking duration, smoking duration is not associated with cessation 
as either a categorical variable or as a continuous variable (data not shown). 
No significant differences were found in the haplotype frequencies between cases and 
controls (p=0.24). Of the 16 potential haplotypes, 12 were included in the best pairs summary for 
the 867 participants with complete genotyping data. The level of certainty for the best pairs was 
greater than 75% for 830 (95.7%) of participants. Of the 12 haplotypes, 5 were present with a 
frequency of at least 5%. These haplotypes are listed in table 16. The remaining haplotypes had a 
combined frequency of 2%. All five haplotypes were evaluated as dichotomous variables 
(presence vs. absence of the haplotype). Haplotype number 4 was further evaluated as a three 
level variable based on the number of copies of the haplotype that were present (0 vs. 1 vs. 2). 
Chi square analyses were significant only for haplotype 4 coded as a three level variable. The 
odds ratios for this variable in relation to smoking cessation are shown in table 17. Having two 
copies of the haplotype significantly increases the odds of quitting. 
3.5 DISCUSSION 
A variety of evidence suggests that the dopamine pathway is involved in smoking behaviors and 
specifically in smoking cessation. The findings from this study further support that hypothesis by 
linking variants in the DRD2 gene to quitting.  
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TaqIA showed the strongest association with quitting both in univariate and multivariate 
analyses. Similar to previous reports [1, 2], we found that participants carrying a variant allele 
were less likely to be abstinent at one year versus those who were homozygous for the wild type 
allele. This association was apparent regardless of whether crude odds ratios were calculated or 
various other genetic and non-genetic variables were included in the model. 
To the best of our knowledge, an interaction between C957T and age has not been 
previously reported. This finding is difficult to explain and is not clarified when the analyses are 
stratified by age. A potential confounder is smoking cessation strategy. For example, if C957T 
genotype interacts with a cessation strategy such as bupropion, and bupropion use varies with 
age, this could explain the observed interaction between C957T and age. Because PLuSS was not 
designed as a smoking cessation study data regarding cessation strategies were not collected.  
We know of only two other studies that investigated the relationship between –141C 
Ins/Del and smoking behavior. One study, conducted in Japan, found no association between –
141C Ins/Del and current, former, and never smokers.[13] Our findings are consistent with that 
report. As with C957T, we may have found differences related to smoking cessation strategy if 
these data were available. Lerman et al. have reported interaction between –141C Ins/Del 
variants and smoking cessation strategies. [9] 
In the haplotype analysis we found that individuals with the A2 B2 T C haplotype were 
more likely to quit smoking than those with other haplotypes, and that this relationship increased 
with the number of copies of the haplotype. When individual allele frequencies are examined in 
relationship to smoking abstinence, only slight differences are seen in allele frequencies between 
continuing smokers and those who were abstinent at one year (data not shown), but the 
combination of alleles (haplotypes) results in a strong association. This suggests that multiple 
variations along the dopamine pathway may influence smoking cessation.   
Our finding that genetics do not appear to be involved in trying to quit but only in 
succeeding in quitting underscores the need for quit strategies that are tailored to interindividual 
differences in smokers. Educational strategies and public awareness of the dangers of smoking 
may increase a person’s motivation to quit, but genetics may determine whether the person 
ultimately succeeds in quitting. 
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Figure 4: Locations of selected variants on the DRD2 gene on Chromosome 11. 
 
 
 
 
 
 
Table 8: Allele frequencies for DRD2 variants q
Allele Frequency Percent
TaqIA
A2 1427 81.0
A1 335 19.0
TaqIB
B2 1521 86.3
B1 241 13.7
C957T
C 752 43.3
T 984 56.7
-141C ins/del
C 1548 88.0
 - 212 12.0  
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Table 9: Subjects (all subjects, Not Abstinent at one year, and Abstinent at one year) distributed 
according to selected baseline characteristics 
Not 
Abstinent Abstinent
Characteristic N % (N=662) (N=219) p-value
Matching Variables
Gender 0.858
men 423 48.0 48.2 47.5
women 458 52.0 51.8 52.5
Age (years) 0.981
50-59 530 60.2 60.3 59.8
60-69 253 28.7 28.5 29.2
70-79 98 11.1 11.2 11.0
Consent Quarter 0.751
01/01/2002 - 03/31/2002 22 2.5 2.0 4.1
04/01/2002 - 06/30/2002 108 12.3 12.7 11.0
07/01/2002 - 09/30/2002 108 12.3 13.0 10.0
10/01/2002 - 12/31/2002 82 9.3 8.8 11.0
01/01/2003 - 03/31/2003 88 10.0 9.7 11.0
04/01/2003 - 06/30/2003 128 14.5 14.8 13.7
07/01/2003 - 09/30/2003 106 12.0 12.1 11.9
10/01/2003 - 12/31/2003 116 13.2 13.1 13.2
01/01/2004 - 03/31/2004 80 9.1 9.1 9.1
04/01/2004 - 06/30/2004 43 4.9 4.8 5.0
Baseline smoking behavior
Intensity (cigarettes per day) 0.060
<20 285 32.3 30.2 38.8
20-39 535 60.7 62.5 55.3
40+ 61 6.9 7.3 5.9
Medical factors
Number of symptoms 0.006
0 139 15.8 15.0 18.3
1 193 21.9 19.8 28.3
2+ 549 62.3 65.3 53.4
Number of conditions 0.177
0 605 68.7 67.2 73.1
1 153 17.4 17.7 16.4
2+ 123 14.0 15.1 10.5
CT screening referral 0.124
yes 427 48.5 47.0 53.0
no 454 51.5 53.0 47.0
Genotypes
Taq1A 0.001
A2/A2 595 67.5 65.6 73.5
A2/A1 237 26.9 29.8 18.3
A1/A1 49 5.6 4.7 8.2
Taq1B 0.060
B2/B2 650 73.8 72.8 76.7
B2/B1 221 25.1 26.4 21.0
B1/B1 10 1.1 0.8 2.3
C957T* 0.200
C/C 175 20.2 21.1 17.2
C/T 402 46.3 46.9 44.7
T/T 291 33.5 32.0 38.1
-141C Ins/Del** 0.870
C/C 692 78.6 78.2 79.8
C/ - 164 18.6 19.0 17.4
- / - 24 2.7 2.7 2.8
Taq1A 0.029
A2/A2 595 67.5 65.6 73.5
Any A1 286 32.5 34.4 26.5
Taq1B 0.255
B2/B2 650 73.8 72.8 76.7
Any B1 231 26.2 27.2 23.3
C957T* 0.214
C/C 175 20.2 21.1 17.2
Any T 693 79.8 78.9 82.8
-141C Ins/Del** 0.624
Smoking behavior on 
Follow-up (%)
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Table 10: Control subjects (Not Abstinent at one year by TaqIA genotype) distributed according to 
selected baseline characteristics 
A2A2 Any A1
Characteristic N % (N=434) (N=228) p-value
Matching Variables
Gender 0.183
men 319 48.2 46.3 51.8
women 343 51.8 53.7 48.2
Age (years) 0.102
50-59 399 60.3 60.4 60.1
60-69 189 28.5 30.2 25.4
70-79 74 11.2 9.4 14.5
Consent Time 0.467
01/01/2002 - 06/30/2002 97 14.7 13.6 16.7
07/01/2002 - 12/31/2002 144 21.8 21.9 21.5
01/01/2003 - 06/30/2003 162 24.5 26.3 21.1
07/01/2003 - 12/31/2003 167 25.2 24.0 27.6
01/01/2004 - 06/30/2004 92 13.9 14.3 13.2
Baseline smoking behavior
Intensity (cigarettes per day) 0.505
<20 200 30.2 29.5 31.6
20-39 414 62.5 62.4 62.7
40+ 48 7.3 8.1 5.7
Medical factors
Number of symptoms 0.305
0 99 15.0 13.8 17.1
1 131 19.8 18.9 21.5
2+ 432 65.3 67.3 61.4
Number of conditions 0.959
0 445 67.2 67.1 67.5
1 117 17.7 18.0 17.1
2+ 100 15.1 15.0 15.4
CT screening referral 0.184
yes 351 53.0 51.2 56.6
no 311 47.0 48.8 43.4
TaqIA Genotype (N=662)
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Table 11: Control subjects (Not Abstinent at one year by TaqIB genotype) distributed according to 
selected baseline characteristics 
B2B2 Any B1
Characteristic N % (N=482) (N=180) p-value
Matching Variables
Gender 0.049
men 319 48.2 45.9 54.4
women 343 51.8 54.1 45.6
Age (years) 0.096
50-59 399 60.3 60.2 60.6
60-69 189 28.5 30.1 24.4
70-79 74 11.2 9.8 15.0
Consent Time 0.644
01/01/2002 - 06/30/2002 97 14.7 13.7 17.2
07/01/2002 - 12/31/2002 144 21.8 22.0 21.1
01/01/2003 - 06/30/2003 162 24.5 25.7 21.1
07/01/2003 - 12/31/2003 167 25.2 24.7 26.7
01/01/2004 - 06/30/2004 92 13.9 13.9 13.9
Baseline smoking behavior
Intensity (cigarettes per day) 0.588
<20 200 30.2 30.1 30.6
20-39 414 62.5 62.0 63.9
40+ 48 7.3 7.9 5.6
Medical factors
Number of symptoms 0.379
0 99 15.0 14.1 17.2
1 131 19.8 19.1 21.7
2+ 432 65.3 66.8 61.1
Number of conditions 0.830
0 445 67.2 66.6 68.9
1 117 17.7 17.8 17.2
2+ 100 15.1 15.6 13.9
CT screening referral 0.043
yes 351 53.0 50.6 59.4
no 311 47.0 49.4 40.6
TaqIB Genotype (N=662)
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Table 12: Control subjects (Not Abstinent at one year by C957T genotype) distributed according to 
selected baseline characteristics 
CC CT
Characteristic N % (N=138) (N=515) p-value
Matching Variables
Gender 0.285
men 315 48.2 44.2 49.3
women 338 51.8 55.8 50.7
Age (years) 0.073
50-59 394 60.3 62.3 59.8
60-69 187 28.6 22.5 30.3
70-79 72 11.0 15.2 9.9
Consent Time 0.121
01/01/2002 - 06/30/2002 97 14.9 17.4 14.2
07/01/2002 - 12/31/2002 144 22.1 18.1 23.1
01/01/2003 - 06/30/2003 162 24.8 21.0 25.8
07/01/2003 - 12/31/2003 164 25.1 24.6 25.2
01/01/2004 - 06/30/2004 86 13.2 18.8 11.7
Baseline smoking behavior
Intensity (cigarettes per day) 0.624
<20 197 30.2 32.6 29.5
20-39 408 62.5 61.6 62.7
40+ 48 7.4 5.8 7.8
Medical factors
Number of symptoms 0.790
0 99 15.2 13.8 15.5
1 131 20.1 21.7 19.6
2+ 423 64.8 64.5 64.9
Number of conditions 0.381
0 441 67.5 63.8 68.5
1 116 17.8 21.7 16.7
2+ 96 14.7 14.5 14.8
CT screening referral 0.684
yes 346 53.0 51.4 53.4
no 307 47.0 48.6 46.6
C957T Genotype (N=653)
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Table 13: Control subjects (Not Abstinent at one year by -141C Ins/Del genotype) distributed 
according to selected baseline characteristics 
CC C -
Characteristic N % (N=518) (N=144) p-value
Matching Variables
Gender 0.050
men 319 48.2 50.2 41.0
women 343 51.8 49.8 59.0
Age (years) 0.538
50-59 399 60.3 60.4 59.7
60-69 189 28.5 27.8 31.3
70-79 74 11.2 11.8 9.0
Consent Time 0.584
01/01/2002 - 06/30/2002 97 14.7 14.5 15.3
07/01/2002 - 12/31/2002 144 21.8 22.6 18.8
01/01/2003 - 06/30/2003 162 24.5 25.3 21.5
07/01/2003 - 12/31/2003 167 25.2 24.1 29.2
01/01/2004 - 06/30/2004 92 13.9 13.5 15.3
Baseline smoking behavior
Intensity (cigarettes per day) 0.739
<20 200 30.2 30.9 27.8
20-39 414 62.5 61.8 65.3
40+ 48 7.3 7.3 6.9
Medical factors
Number of symptoms 0.173
0 99 15.0 16.2 10.4
1 131 19.8 20.1 18.8
2+ 432 65.3 63.7 70.8
Number of conditions 0.093
0 445 67.2 69.3 59.7
1 117 17.7 16.4 22.2
2+ 100 15.1 14.3 18.1
CT screening referral 0.165
yes 351 53.0 54.4 47.9
no 311 47.0 45.6 52.1
-141C Ins/Del Genotype 
(N=661)
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Table 14: Crude and adjusted odds ratios for the effect of genotype on one-year quit status. 
Abstinent Not Abstinent
Genotype OR 95% CI p-value^ OR 95% CI p-value^^ OR 95% CI p-value^^
TaqIA 0.030 0.027 0.033
A2/A2 161 434 1.00 (reference) 1.00 (reference) 1.00 (reference)
Any A1 58 228 0.69 (0.49-0.96) 0.68 (0.48-0.96) 0.47 (0.24-0.94)
TaqIB 0.256 0.239 0.184
B2/B2 168 482 1.00 (reference) 1.00 (reference) 1.00 (reference)
Any B1 51 180 0.81 (0.57-1.16) 0.80 (0.56-1.16) 1.66 (0.79-3.51)
C957T 0.214 0.153 0.261
CC 82 209 1.00 (reference) 1.00 (reference) 1.00 (reference)
Any T 133 444 1.29 (0.86-1.93) 1.35 (0.90-2.03) 1.29 (0.83-2.02)
-141C Ins/Del
C/C 174 518 1.00 (reference) 0.624 1.00 (reference) 0.561 1.00 (reference) 0.900
Any Del 44 144 0.91 (0.62-1.33) 0.892 (0.61-1.31) 0.98 (0.65-1.45)
^Chi-square test
^^Wald Test
**Model 2 uses logistic regression to adjust the genotype-smoking outcome associations (expressed as odds ratios) for matching factors and for 
each of the other genetic risk factors. N=867
Crude Model set 1* Model 2**
*Model Set 1 uses logistic regression to adjust the genotype-smoking outcome associations (expressed as odds ratios) for factors (gender, decade 
of age, and quarter of enrollment) used to match the case and controls groups. N=881 for the TaqIA and TaqIB models. N=868 fo the C957T model. 
N=880 for the -141C Ins/Del model.
 
 
Table 15: An evaluation of the interaction term C957T X decade of age in relation to smoking status 
at one year 
 
Decade of Age Abstinent C/C Any T p-value
50s 0.02
Yes 16 (12.5) 112 (87.5)
No 86 (21.8) 308 (78.2)
1.00 2.13 (1.18-3.83)
60s 0.07
Yes 17 (27.0) 46 (73.0)
No 31 (16.6) 156 (83.4)
1.00 0.52 (0.26-1.05)
70s 0.23
Yes 4 (16.7) 20 (83.3)
No 21 (29.2) 51 (70.8)
1.00 1.93 (0.54-6.87)
*Adjusted for gender and time of enrollment (3 month intervals)
OR (95% CI)*
OR (95% CI)*
OR (95% CI)*
DRD2-957 Genotype Distributions (%)
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Table 16: Most frequent haplotypes for all 881 participants 
Taq1A Taq1B C957T -141C Insdel Frequency
1 A2 B2 C C 0
2
.20
A2 B2 C Del 0
4
.08
A2 B2 T C 0
8
.50
A1 B1 C C 0
10
.12
A1 B2 T C 0
Alleles Included in Each HaplotypeHaplotype 
Numbe
.08
r
 
 
 
 
 
Table 17: Odds of being abstinent at one year based on the number of copies of haplotype 4, limited 
to participants with haplotype pairs that were determined with a certainty of more than 75% (N=830) 
Number of copies of haplotype 4 OR 95% CI
1 versus 0 1.03 (0.68, 1.54)
2 versus 0 1.57 (1.02, 2.41)
2 versus 1 1.55 (1.07, 2.23)
Adjusted for adjusted for decade of age, gender, and time of enrollment 
(3 month intervals)  
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4.0  SMOKING AND THE DOPAMINE PATHWAY: VARIANTS OF THE 
DOPAMINE TRANSPORTER GENE 
4.1 ABSTRACT 
Introduction 
Dopamine availability may explain differences in responses to smoking and smoking cessation. 
Dopamine transporter (DAT) is a reuptake protein coded by the SLC6A3 gene that removes 
dopamine from the synapse. Variations in SLC6A3 may impact the number of transporter 
molecules on the surface of neurons and the functionality of DAT.  
 
Objective 
This study attempts to determine genetic influences on the relationship between the dopamine 
pathway and smoking cessation by examining a variable number tandem repeat in the SLC6A3. 
 
Participants 
Participants are part of the Pittsburgh Lung Screening Study (PLuSS), a research based low-dose 
CT screening program containing current and former cigarette smokers, ages of 50 to 79 years, 
recruited from the general population in the Pittsburgh area. Eligible members of the cohort must 
have smoked at least one-half pack per day for at least 25 years.  
 
Methods 
Questionnaire data from all baseline smokers who provided information on smoking status one 
year later were evaluated. Subjects were classified as Not Abstinent at one year or Abstinent at 
one year according to smoking status information that they provided during the one year 
telephone follow-up. All eligible participants who were Abstinent at one year (n=225) were 
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included in the genotype analysis. Those in the Not Abstinent group were frequency matched to 
the Abstinent at one year group by gender, decade of age, and time of enrollment (three month 
intervals) in a three to one ratio (n=675). SLC6A3 data (genotype with respect to the number of 
40 base-pair repeats in the 3’ untranslated region of the SLC6A3) were available for 219 in the 
Abstinent at one year group and 662 in the Not Abstinent at one year group. Logistic regression 
was used to identify the effect of genotype on abstinence at one year. 
 
Results/Conclusion 
SLC6A3 genotype was not associated with smoking status at one-year (p=0.757). After adjusting 
for matching variables, compared to participants with the 10-repeat/10-repeat genotype the odds 
ratio for being Abstinent at one year in participants with the 10-repeat/9-repeat genotype was 
1.10 (95% CI: 0.79-1.54) and with the 9-repeat/9-repeat genotype was 0.90 (95% CI: 0.50-1.62). 
Contrary to previous reports no significant gene-gene interaction with the DRD2 TaqIA variant 
was observed. 
4.2 INTRODUCTION 
The dopamine pathway is a major reward pathway implicated in addiction to nicotine and other 
drugs. Dopamine receptors, which are stimulated by dopamine, have been the focus of a majority 
of research related to potential associations between dopamine and addiction. It has been 
hypothesized that differences in the density of receptors may explain the interindividual 
differences in response to the dopamine release that occurs in smokers. However, other factors, 
such as the amount of dopamine available, may also explain these differences. Dopamine 
transporter (DAT) is a reuptake protein that removes dopamine from the synapse. This protein is 
coded by the SLC6A3 gene.  
The SLC6A3 gene is located on chromosome 5p15.3.[1] DAT’s role in removing 
dopamine from the synapse has led to research on SLC6A3 and various dopamine-related 
disorders. Variations in a 40-base pair repeat in the 3’ untranslated region have been linked to 
variations in the density of transporter molecules on the surface of neurons.[1] The 10-repeat 
allele (wild type) and the 9-repeat allele are the most frequently occurring variants, although a 
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wide range of repeats have been found. Laboratory studies suggest that variations in the number 
of repeats influence variations in gene transcription and expression.[2-5] 
Two studies have found an association between reduced smoking behaviors and presence 
of the 9-repeat allele of SLC6A3. Sabol et al., found a significant association between SLC6A3 
genotype and smoking cessation among 593 nonsmokers (less than 100 cigarettes), 283 current 
smokers, and 231 former smokers. The 9-REPEAT ALLELE allele was more common among 
former smokers compared to those who were current smokers.[6] Similarly, Lerman et al., 
reported that the 9-repeat allele was found less frequently among a group of 289 smokers when 
compared to 233 non-smokers (less than 100 cigarettes). The Lerman report also compared 
DRD2 variant allele frequencies. No differences were found between smokers and non-smokers 
in the prevalence of the TaqIA variant; however, the study suggested that DRD2 may modify the 
effects of SLC6A3.[7] In a subsequent randomized trial of bupropion for smoking cessation, 
SLC6A3 was not significant as a main effect in the entire sample, but was significant among 
participants with the DRD2 TaqIA A2A2 genotype. In the multivariate model in the entire 
sample, the DRD2  SLC6A3 interaction term was significant.[8]  
In contrast, Vandenberg, et al., reported no relationship between SLC6A3 and smoking 
behavior among 595 randomly selected adult volunteers when the same group classifications 
were used that were used in the previously described reports (nonsmokers who smoked <100 
cigarettes, former smokers, current smokers). However contrary to the previously reported 
associations, when never-smokers (0 lifetime cigarettes) and non-smokers (<100 lifetime 
cigarettes) were analyzed as separate groups, the 10-repeat allele was more frequent among 
never smokers. [1] Jorm et al. found no association between the SLC6A3 gene and either 
smoking initiation or cessation.[9] 
4.3 METHODS 
4.3.1 Population 
This study focuses on participants in the Pittsburgh Lung Screening Study (PLuSS). PLuSS is a 
low-dose computer tomography (CT) screening program conducted as part of the University of 
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Pittsburgh Lung Cancer SPORE research program. PLuSS participants were recruited from 
January, 2002 until April, 2005. Current and former cigarette smokers between the ages of 50 
and 79 years were eligible for the PLuSS. Participants must have smoked at least one-half pack 
per day for at least 25 years. Baseline data collection included a questionnaire, CT scan and 
pulmonary function test. A CT scan and brief telephone follow-up questionnaire were completed 
approximately one year after the baseline CT.  
Between August, 2005 and January, 2006 we measured expired air carbon monoxide in a 
subset of 228 PLuSS participants during their follow-up CT scan appointment. Participants were 
asked their smoking status prior to taking the test. A total of 229 carbon monoxide readings were 
compared to self-reported smoking status. A reading of 8 parts per million or higher was 
considered a positive test for smoking.[10] Of the 108 participants who reported not smoking 13 
(12%) tested positive, and of the 121 participants who reported that they were smoking 9 (7%) 
tested negative.  
We selected a subset of PLuSS participants who were smoking at baseline and had 
provided information regarding their smoking status at follow-up for the genotyping analysis 
excluding those who had lung cancer diagnosed in the one-year follow-up interval. This subset 
was limited to Caucasians due to the high proportion of Caucasians in the PLuSS population 
(over 90%). Smoking status was assessed during the one-year telephone follow-up questionnaire. 
Participants were classified as Abstinent at one year (cases) if they reported that were not 
smoking and had remained abstinent for more than 30 days prior to the follow-up questionnaire. 
Participants were classified as Not Abstinent at one year (controls) if they reported that they 
were currently smoking. Subset selection occurred in October, 2004 and July, 2005. The subset 
included all in the Abstinent at one year group. Participants in the Not Abstinent at one year 
group were matched in a three to one ratio to the Abstinent at one year group in gender, decade 
of age, and time of enrollment (in three month intervals) strata. If a stratum did not contain 
enough participants who were not abstinent at one year, matching was conducted using an 
adjacent time of enrollment or decade of age stratum. Of the 900 specimens that were requested 
(225 Abstinent, 675 Not Abstinent), 881 were available and successfully genotyped (219 
Abstinent, 662 Not Abstinent). 
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4.3.2 Genotyping Procedures 
The SLC6A3 40 bp VNTR in the 3’-untranslated region was determined by a PCR-based assay 
adapted from Kang, et al with minor modification.[11] Briefly, each 25 μl reaction contained  1X 
PCR Optimized Buffer B (InVitrogen, Carlsbad, CA), 5% DMSO, 200 μM of dNTP, 900 μM of 
primers, 1.2 units of AmpliTaq Gold (Applied Biosystems, Foster City, CA) and 20ng of 
genomic DNA. Thermal cycling was initiated with 94° C activation for 10 minutes, followed by 
40 cycles of 1 minute at 94° C and 3 minutes at 72° C ending with a 72° C extension for 10 min.  
The PCR products were electrophoresed on 8% polyacrylamide gels using the 50bp gel marker 
(Fisher Science) to determine PCR product length.  Each gel also included two known 
heterozygote genotype samples as positive controls (8/9 repeats and 9/10 repeats) and one 
negative PCR control sample. An additional 10% of samples was repeated to verify the 
reproducibility of the assay. All results were interpreted independently by two laboratory 
personnel who were blinded to the case-control status of participants. In the event of a 
discrepancy, the genotyping assay was repeated until concordance was reached. 
4.3.3 Data Analysis 
Matching variables included Gender (male vs. female), Age (by decade of life at baseline), and 
Consent Date (by quarter). Potential risk factors for quitting included the following demographic 
variables: Education (high school or less vs. other), and Marital Status (married/living as married 
vs. divorced/separated/widowed vs. never married). Other potential risk factors included health-
related variables such as Family History of Any Cancer (yes vs. no), Family History of Lung 
Cancer (yes vs. no), Personal History of Any Cancer Except Lung (yes vs. no), Number of 
Symptoms of lung disease (0 vs. 1 vs. 2 or more), Number of Health Conditions (0 vs. 1 vs. 2 or 
more), and Referral required due to abnormal CT finding (yes vs. no). Smoking history variables 
included Start Age (continuous), Baseline Cigarettes Per Day (less than 20 vs. 20 to 39 vs. 40 or 
more), Smoking Duration (continuous) and Smoking Duration (less than 46 years or 46 years or 
more). The SLC6A3 allele was examined by genotype (10/10 vs. 10/9 vs. 9/9) and by presence or 
absence of 9- repeat allele. To examine possible interaction between DRD2 and SLC6A3, DRD2 
genetic variables were examined by genotype (TaqIA: A1A1 vs. A1A2 vs. A2A2; TaqIB: B1B1 vs. 
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B1B2 vs. B2B2; C957T: CC vs. CT vs. TT; -141C ins/del: CC, C-, --) and by presence or absence 
of the variant allele. 
The relationships between all variables and one-year smoking status were initially 
assessed using univariate analysis techniques (chi-squared tests, t-tests, and Fisher’s exact tests 
as appropriate). The focus of the analysis was to determine the impact of SLC6A3 genotype on 
smoking cessation, so univariate tests also included an evaluation of relationships between the 
SLC6A3 variables and other variables. Logistic regression was used to develop an overall risk 
model for smoking cessation. Matching variables were forced into the regression model. 
Potential risk factors that were significantly associated with smoking status in the univariate 
analysis were included in the model building analysis as were predictor variables that showed 
associations with smoking status in a previous evaluation of the PLuSS population. Once the best 
fitting model was established without the genetic variables, the genetic variables were added. 
Building on a previous analysis that investigated the relationship of DRD2 to smoking 
cessation, we added SLC6A3 to a model that included only the DRD2 variables to determine if 
SLC6A3 had an impact on the relationship between these variables and smoking cessation. 
4.4 RESULTS 
Table 18 displays the allele frequencies which are consistent with frequencies reported in the 
literature for Caucasians. Aside from the most common 9- and 10-repeat alleles other alleles in 
our sample included 6-, 7-, 8-, 11-, and 12-repeat alleles. Table 19 shows the relationships of risk 
factor variables and genetic variables with smoking cessation. Number of symptoms at baseline 
(p=0.006) was the only predictor variable that was significantly associated with smoking 
behavior at one year. SLC6A3 was not significantly associated with smoking cessation or with 
any of the matching or risk factor variables (See tables 19 and 20).  
Odds ratios were calculated for SLC6A3 genotypes and the presence of the 9-repeat allele 
(table 21). No statistically significant differences in abstinence at one year were found between 
SLC6A3 genotypes, and no statistically significant association between the presence of the 9-
repeat allele and abstinence at one year were observed. Compared to participants with the 10/10 
genotype, the crude odds ratio for quitting in participants with the 10/9 genotype was 1.08 (95% 
 63 
CI: 0.78-1.51) and with the 9/9 genotype was 0.89 (95% CI: 0.50-1.58). After adjusting for 
matching variables, compared to participants with the 10/10 genotype, the odds ratio for quitting 
in participants with the 10/9 genotype was 1.10 (95% CI: 0.79-1.54) and with the 9/9 genotype 
was 0.90 (95% CI: 0.50-1.62). Similarly both the adjusted and unadjusted odds ratios for 
smoking abstinence in the presence of a 9-repeat allele were close to 1.00. See table 21. 
Based on a previous analysis of those data, the model building analysis began with a base 
model that included the matching variables (gender, decade of age, and quarter of consent) and 
number of symptoms. When we added SLC6A3 to the base model, we found that it did not 
contribute to the model as either a three level variable (10/10 vs. 10/9 vs. 9/9) or as a two-level 
variable (presence of 9-repeat allele). SLC6A3 was not significant in additional analyses 
comparing those who tried (regardless of success) to those who did not try to quit and comparing 
those who had made a quit attempt but were not abstinent at one year to those were abstinent at 
one year (data not shown).  
The DRD2 variables were added into the model that contained SLC6A3, the matching 
variables, and number of symptoms to see if the DRD2 variables influenced the relationship 
between SLC6A3 and smoking cessation. Consistent with a previous analysis of these data, 
TaqIA was significantly associated with smoking behavior at one year both by genotype and by 
presence or absence of the A1 allele; however, the interaction term with SLC6A3 was not 
significant. TaqIB (by genotype) showed a trend for an association with smoking behavior until 
TaqIA was added back into the model. C957T and –141C Ins/Del were not significantly 
associated with smoking cessation in a model that included SLC6A3, and no interaction with 
SLC6A3 was evident. (Data not shown.) 
Although interaction terms were not significant in the regression model, previous studies 
have reported interaction between SLC6A3 and DRD2.[7, 8] To investigate this interaction, we 
evaluated the relationships between presence or absence of the 9-repeat allele and smoking 
behavior stratified by presence or absence of the DRD2 TaqIA A1 allele (table 22). No 
statistically significant interaction between DRD2 TaqIA and SLC6A3 was evident (p=0.381). 
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4.5 DISCUSSION 
Our findings are consistent with those of Jorm et al. in that we found no direct association 
between smoking and variation in the SLC6A3 gene. These findings are contrary to initial reports 
by Lerman et al. and Sabol et al.  
Differences in study populations must be considered in comparing the current findings to 
previous findings. The initial Lerman study compared Caucasian and African-American non-
smokers (smoked less than 100 cigarettes per day) to current smokers (at least 5 cigarettes per 
day for at least 1 year). Self-reported non-smokers with an exhaled air carbon monoxide level of 
8 ppm or higher were excluded. The total study sample was smaller than the current study (521 
total or 444 Caucasians in the Lerman study vs. 881 Caucasians in the current study).[7] The 
most significant difference between the Lerman study and the current study is that the Lerman 
study did not specifically address smoking cessation.  If the genetic influences on smoking 
initiation, specifically initiation of smoking on a regular basis, and on smoking cessation differ, 
then comparisons cannot be made between the two studies.  
The Sabol study looked at smoking cessation by comparing former smokers to current 
smokers. In contrast to the current study, the Sabol study was not restricted to Caucasians but 
was predominately Caucasian (83.9%). When comparisons in the Sabol study were limited to 
only current and former smokers, the sample size was 514 (283 current, 231 former). The 
unadjusted odds ratio for being a former smoker with a 9-repeat allele versus no 9-repeat allele 
was 1.49 (95% CI: 1.05-2.11).[6] When we used the same methods to calculate the unadjusted 
odds ratio our odds ratio (OR: 1.02, 95% CI: 0.75-1.39) comes close to the 95% CI reported by 
Sabol but does not reach statistical significance.  
The Jorm study was restricted to Caucasians in Australia. As in the Sabol study, the Jorm 
study looked at smoking cessation by comparing current smokers to former smokers. For this 
comparison the sample size was 409 (198 current, 211 former). The unadjusted odds ratio for the 
Jorm study is consistent with our finding (OR: 1.16, 95% CI: 0.79-1.72).[9]  
In both, a study of non-smokers versus smokers and a study of individuals who quit 
smoking after bupropion treatment versus those who did not quit after bupropion treatment, 
Lerman reported a DRD2(TaqIA) by SLC6A3 gene-gene interaction. In both reports, the 9- repeat 
allele was only significant among individuals with the TaqIA A2A2 genotype.[7, 8] We found no 
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significant effect of SLC6A3 on smoking status even after stratifying by the presence of the A1 
allele (table 22). Therefore, larger single population studies or pooled analyses are needed to 
clarify the nature of the relationship between TaqIA and SLC6A3 with respect to smoking 
behaviors. 
The disparate findings across these four studies highlight the need for replication studies 
in gene-disease association studies. Small differences in sample selection with regard to the 
definition of cases and controls, ethnic composition and sample size could influence the study 
findings. 
 
Table 18: SLC6A3 allele frequencies 
Allele Frequency Percent
10 1281 72.7
9 463 26.3
Other 18 1.0  
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Table 19: Subjects (all subjects, Not Abstinent at one year, and Abstinent at one year) distributed 
according to selected baseline characteristics. 
Not 
Abstinent Abstinent
Characteristic N % (N=662) (N=219) p-value
Overall 881 100.0 75.1 24.9
Matching Variables
Gender 0.858
men 423 48.0 48.2 47.5
women 458 52.0 51.8 52.5
Age (years) 0.981
50-59 530 60.2 60.3 59.8
60-69 253 28.7 28.5 29.2
70-79 98 11.1 11.2 11.0
Consent Quarter 0.751
01/01/2002 - 03/31/2002 22 2.5 2.0 4.1
04/01/2002 - 06/30/2002 108 12.3 12.7 11.0
07/01/2002 - 09/30/2002 108 12.3 13.0 10.0
10/01/2002 - 12/31/2002 82 9.3 8.8 11.0
01/01/2003 - 03/31/2003 88 10.0 9.7 11.0
04/01/2003 - 06/30/2003 128 14.5 14.8 13.7
07/01/2003 - 09/30/2003 106 12.0 12.1 11.9
10/01/2003 - 12/31/2003 116 13.2 13.1 13.2
01/01/2004 - 03/31/2004 80 9.1 9.1 9.1
04/01/2004 - 06/30/2004 43 4.9 4.8 5.0
Baseline smoking behavior
Intensity (cigarettes per day) 0.060
<20 285 32.3 30.2 38.8
20-39 535 60.7 62.5 55.3
40+ 61 6.9 7.3 5.9
Medical factors
Number of symptoms 0.006
0 139 15.8 15.0 18.3
1 193 21.9 19.8 28.3
2+ 549 62.3 65.3 53.4
Number of conditions 0.177
0 605 68.7 67.2 73.1
1 153 17.4 17.7 16.4
2+ 123 14.0 15.1 10.5
CT screening referral 0.124
yes 427 48.5 47.0 53.0
no 454 51.5 53.0 47.0
Genetic Variables
Genotype* 0.773
10/10 481 55.7 54.8 53.9
10/9 307 35.5 34.3 36.5
9/9 76 8.8 8.9 7.8
Any SLC6A3-9 0.900
Yes 387 43.9 43.8 44.3
No 494 56.1 56.2 55.7
*Excludes 17 participants with alleles other than 10-repeat or 9-repeat
Smoking behavior on 
Follow-up (%)
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Table 20: Control subjects (Not Abstinent at one year by SLC6A3 genotype) distributed according to 
selected baseline characteristics 
No Yes
Characteristic N % (N=372) (N=290) p-value
Matching Variables
Gender 0.968
men 319 48.2 48.1 48.3
women 343 51.8 51.9 51.7
Age (years) 0.671
50-59 399 60.3 61.0 59.3
60-69 189 28.5 28.8 28.3
70-79 74 11.2 10.2 12.4
Consent Time 0.823
01/01/2002 - 03/31/2002 13 2.0 2.4 1.4
04/01/2002 - 06/30/2002 84 12.7 13.7 11.4
07/01/2002 - 09/30/2002 86 13.0 13.2 12.8
10/01/2002 - 12/31/2002 58 8.8 9.1 8.3
01/01/2003 - 03/31/2003 64 9.7 8.9 10.7
04/01/2003 - 06/30/2003 98 14.8 14.8 14.8
07/01/2003 - 09/30/2003 80 12.1 11.3 13.1
10/01/2003 - 12/31/2003 87 13.1 13.2 13.1
01/01/2004 - 03/31/2004 60 9.1 9.7 8.3
04/01/2004 - 06/30/2004 32 4.8 3.8 6.2
Baseline smoking behavior
Intensity (cigarettes per day) 0.917
<20 200 30.2 29.8 30.7
20-39 414 62.5 63.2 61.7
40+ 48 7.3 7.0 7.6
Medical factors
Number of symptoms 0.426
0 99 15.0 16.1 13.4
1 131 19.8 20.7 18.6
2+ 432 65.3 63.2 67.9
Number of conditions 0.213
0 445 67.2 67.7 66.6
1 117 17.7 19.1 15.9
2+ 100 15.1 13.2 17.6
CT screening referral 0.555
yes 311 47.0 46.0 48.3
no 351 53.0 54.0 51.7
Any SLC6A3 9-repeat allele (N=649)
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Table 21:Crude and adjusted odds ratios for the effect of SLC6A3 genotype on one-year quit status. 
Abstinent Not Abstinent
SLC6A3 OR 95% CI p-value^ OR 95% CI p-value^
Genotype' 0.773 0.757
10/10 118 363 1.00 (reference) 1.00 (reference)
9/10 80 227 1.08 (0.78-1.51) 1.10 (0.79-1.54)
9/9 17 17 0.89 (0.50-1.58) 0.90 (0.50-1.62)
Any 9-repeat allele 0.900 0.822
No 97 290 1.00 (reference) 1.00 (reference)
Yes 122 372 1.02 (0.75-1.39) 1.04 (0.76-1.41)
'Participants who had an SLC6A3 allele other than 9-repeat or 10-repeat were excluded. N=864
Crude OR Adjusted OR+
+Adjusted for factors (gender, decade of age, and quarter of enrollment) used to match the case and control 
groups. 
^Wald Test
 
 
 
 
Table 22: An evaluation of the interaction between TaqIA and SLC6A3 
TaqIA Abstinent at one year No Yes p-value^
A2/A2
Yes 70 (26.8) 91 (27.2) 0.908
No 191 (73.2) 243 (72.8)
1.00 1.02 (0.71-1.48)
A2/A1 or A1/A1
Yes 31 (19.4) 27 (21.4) 0.668
No 129 (80.6) 99 (78.6)
1.00 1.08 (0.60-1.97)
^ p-value for chi-square test
*Adjusted for gender, decade of age, and time of enrollment (3 month intervals)
p=0.381 (Log liklihood ratio test) for interaction between TaqIA and SLC6A3
SLC6A3-9
OR (95% CI)*
OR (95% CI)*
 
 
 69 
 4.6 REFERENCES 
1. Vandenbergh, D.J., et al., Smoking status and the human dopamine transporter variable 
number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that 
never-smokers may be different.[see comment]. Nicotine & Tobacco Research, 2002. 
4(3): p. 333-40. 
2. Michelhaugh, S.K., et al., The dopamine transporter gene (SLC6A3) variable number of 
tandem repeats domain enhances transcription in dopamine neurons. Journal of 
Neurochemistry, 2001. 79(5): p. 1033-8. 
3. Fuke, S., et al., The VNTR polymorphism of the human dopamine transproter (DAT1) 
gene affects gene expression. The Pharmacogenomics Journal, 2001. 1: p. 152-156. 
4. Jacobsen, L.K., et al., Prediction of dopamine transporter binding availability by 
genotype: a preliminary report. American Journal of Psychiatry, 2000. 157(10): p. 1700-
3. 
5. van Dyck, C.H., et al., Increased dopamine transporter availability associated with the 9-
repeat allele of the SLC6A3 gene. Journal of Nuclear Medicine, 2005. 46: p. 745-51. 
6. Sabol, S.Z., et al., A genetic association for cigarette smoking behavior.[comment]. 
Health Psychology, 1999. 18(1): p. 7-13. 
7. Lerman, C., et al., Evidence suggesting the role of specific genetic factors in cigarette 
smoking.[comment]. Health Psychology, 1999. 18(1): p. 14-20. 
8. Lerman, C., et al., Effects of dopamine transporter and receptor polymorphisms on 
smoking cessation in a bupropion clinical trial. Health Psychology, 2003. 22(5): p. 541-
8. 
9. Jorm, A.F., et al., Association of smoking and personality with a polymorphism of the 
dopmaine transporter gene: Results from a community survey. American Journal of 
Medical Genetics, 2000. 96: p. 331-4. 
10. SRNT Subcommittee on Biochemical Verification, Biochemical verification of tobacco 
use and cessation. Nicotine & Tobacco Research, 2002. 4(2): p. 149-59. 
11. Kang, A.M., M.A. Palmatier, and K.K. Kidd, Global variation of a 40-bp VNTR in the 3'-
untranslated region of the dopamine transporter gene (SLC6A3). Biological Psychiatry, 
1999. 46(2): p. 151-60. 
 
 70 
5.0  OVERALL DISCUSSION 
5.1 MAJOR FINDINGS 
In an investigation of non-genetic factors associated with smoking cessation one year after entry 
into a lung screening study (PLuSS), we found that having a computed tomography (CT) scan of 
the lungs that resulted in a referral was significantly associated with abstinence at one year. The 
relative risk of being in the Successful Quitter group after receiving a CT referral was 1.39 (95% 
Confidence Interval (CI): 1.14-1.70). Even after controlling for marital status, gender, symptoms 
of lung disease, and pulmonary conditions, a CT referral was significantly related to quitting 
behavior (p<0.001). Relative to participants with CT results not resulting in a referral, 
participants who had CT results necessitating a referral were more often in the Unsuccessful 
Quitter group (OR: 1.43, 95% CI: 1.17-1.74, compared to Nonquitter) and to be in the Successful 
Quitter group (OR: 1.24, 95% CI: 0.96-1.61, compared to Unsuccessful Quitter). This 
association supports the notion that CT screening can influence smoking behaviors thereby 
creating a “teachable moment” for smoking interventions. 
We also investigated the impact of DRD2 polymorphisms (TaqIA A1 vs. A2, TaqIB B1 
vs. B2, C957T C vs. T, –141C Ins/Del C vs. – ) on smoking status one year after entry into 
PLuSS. After controlling for the matching variables and other genotypes, the DRD2 TaqIA 
polymorphism was significantly associated with being abstinent at one year (p=0.01). Compared 
to participants who had the homozygous wild type TaqIA genotype (A2A2), participants who 
carried at least one variant allele (A1) were less likely to quit (Odds Ratio: 0.47, 95% CI: 0.24-
0.94). This association supports the hypothesis that genetic variation in the dopamine pathway 
influences smoking cessation.  
We also looked at the contribution of the dopamine transporter SLC6A3 VNTR 
polymorphism which occurs primarily as a 9- or 10- repeat allele. SLC6A3 genotype was not 
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associated with smoking status at one-year (p=0.757). After adjusting for matching variables, 
compared to participants with the 10/10 genotype the odds ratio for being Abstinent at one year 
in participants with the 10/9 genotype was 1.10 (95% CI: 0.79-1.54) and with the 9/9 genotype 
was 0.90 (95% CI: 0.50-1.62). Contrary to previous reports no significant gene-gene interaction 
with the DRD2 TaqIA variant was observed. 
5.2 STRENGTHS 
The focus of this study is smoking cessation. Therefore, a strength of this study is that it isolates 
the period of time on the smoking continuum in which participants quit smoking. Participants in 
this study are fairly homogenous with respect to their smoking histories; thus, limiting the 
potential effect of genotype on smoking duration and intensity. Genetic association studies are 
frequently criticized for attempting to find an association between a single gene and disease 
because it is highly likely that groups of genes or variants contribute to disease. Although still 
limited in number, a strength of this study is that it investigates the contribution of several 
genetic variants on the dopamine pathway. This study, with a sample size of nearly 900 
participants, is also among the largest of the studies that have looked at associations between the 
dopamine pathway and smoking behavior. 
5.3 LIMITATIONS 
Potential misclassification bias: I classified participants as smokers or quitters based on their 
answer to the telephone follow-up questionnaire question, “Are your currently smoking?” I 
estimated the overall accuracy of self-report in the PLuSS population by conducting exhaled air 
carbon monoxide tests in a subset of participants who returned for the one-year CT scan. Overall, 
I found approximately 90% agreement between self-reported smoking status and carbon 
monoxide levels using 8 parts per million (ppm) or higher to classify smokers with slightly lower 
agreement among those with a reading of 8 ppm or higher (88%) compared to those with a 
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reading below 8 ppm (93%). Because participants are unaware of their genotype, it is unlikely 
that misclassification will be differential with respect to genotype. Hence, misclassification with 
respect to smoking status would be expected to bias the observed association between genes and 
smoking outcome toward the null (no association). 
Limited number of genes: The inability to quit smoking is most likely influenced by 
many factors and multiple genes. No single gene or set of genes has been identified as the most 
important determinant of smoking cessation. DRD2 was initially selected because a strong 
biological rationale exists for the involvement of the dopamine pathway in smoking cessation, 
smoking behaviors in general, and because assays for most of the variants had already been 
developed. SLC6A3, also part of the dopamine pathway, was selected because of the potential for 
interaction with DRD2. 
Limited generalizability: Frequencies of the genetic variants of interest are known to 
differ among ethnic groups. The sample for the genetic studies was limited to Caucasian subjects 
because the small number of non-Caucasians in the parent populations made subgroup analyses 
impossible. However, because of this limitation the results cannot be applied to the general 
population. 
This study also included only individuals who self-selected into a lung cancer screening 
study. These individuals may differ from individuals in the general population with regard to 
their motivations for quitting and their experiences with smoking cessation attempts in the past.  
Potential selection bias: Because my primary endpoint was smoking status at one year, 
participants who did not complete the one year follow-up questionnaire were excluded from the 
study. Without data from the one-year follow-up it is impossible to determine if smoking status 
at one year is associated with completing the follow-up questionnaire. However, the completion 
rates for the one-year follow-up were quite high particularly when only those participants who 
were eligible for follow-up were considered (97%). Of the baseline smokers who lacked follow-
up data, many were not yet due for follow-up. 
Lack of environmental data: The parent study, PLuSS, was designed as a lung cancer 
screening study, not a smoking cessation study. Therefore, limited data were collected regarding 
smoking behaviors, exposure to second hand smoke, social pressure and motivations related to 
smoking behavior. These environmental data could modify the effects of genotype on smoking 
cessation.  
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Possible confounding by cessation strategy: The ultimate goal of genotyping analyses 
related to smoking cessation is to develop tailored cessation strategies by genotype. Although we 
did not find significant results for some variants when we assessed quit status, if data were 
available regarding quit strategy we may have found associations between genotype and quit 
strategy. 
5.4 FUTURE RESEARCH 
This study provides a basis on which I can expand my investigation of smoking cessation in 
several ways. As I described previously, there are a number of candidate genes that could 
influence smoking cessation. A study of this population is currently underway investigating the 
effect of CYP2A6 polymorphisms on smoking cessation. Additional studies could expand the 
gene panel further.  
For my dissertation work I chose to limit the genotyping analysis to PLuSS participants 
who were smoking at baseline. However, with additional funding I could expand my sample to 
include individuals who had quit smoking before the baseline assessment.  
Future studies could be designed to obtain additional information regarding cessation 
attempts, environment, and health provider messaging for tobacco abstinence during the period 
of interest. These studies could also include additional evaluations of smoking status, such as a 
cotinine test, among all participants at the time of self-report. 
5.5 APPLICATION TO PUBLIC HEALTH 
Cigarette smoking is the leading preventable cause of death in the United States.[1] Although 
strategies are in place to prevent children and young adults from initiating smoking, half of all 
adults have smoked in their lifetime and over half continue to smoke. A vast majority of these 
smokers want to quit, but have been unable to do so.[2] 
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Although a variety of behavioral and pharmacological smoking cessation aides are 
available, most individuals who quit successfully do so without any assistance.[1] The limited 
effectiveness of cessation aides in the population may be due to interindividual differences in 
various aspects of smoking behavior including both the strength of addiction and the burden of 
withdrawal symptoms. These interindividual differences are partially dictated by genetics. 
Therefore, identification of genetic influences on smoking behavior and consideration of those 
influences in the selection of quitting regimens may improve success rates thereby reducing the 
morbidity and mortality due to continued cigarette smoking. 
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